Radiotherapy for subfoveal choroidal neovascularisation in age-related macular degeneration by Bergink, G.J.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/146526
 
 
 
Please be advised that this information was generated on 2021-11-03 and may be subject to
change.
RADIOTHERAPY FOR SUBFOVEAL CHOROIDAL 
NEOVASCULARISATION IN AGE-RELATED 
MACULAR DEGENERATION 
:.Jëfc . 
G.J. BERGINK 

RADIOTHERAPY FOR SUBFOVEAL CHOROIDAL 
NEOVASCULARISATION IN AGE-RELATED MACULAR 
DEGENERATION 
A clinical study in patients with age-related subfoveal 
neovascular macular degeneration 
Cover illustration: Top, subfoveal age-related choroidal neovascularization of a right eye 
(color). Bottom, fluorescein angiogram of the same eye. 
V 
V Printed by: Haveka В V , Alblasserdam, The Netherlands 
RADIOTHERAPY FOR SUBFOVEAL CHOROIDAL 
NEOVASCULARISATION IN AGE-RELATED MACULAR 
DEGENERATION 
Een wetenschappelijke proeve op het gebied van de 
MEDISCHE WETENSCHAPPEN 
Proefschrift 
ter verkrijging van de graad van doctor 
aan de Katholieke Universiteit Nijmegen, 
volgens besluit van het College van Decanen 
in het openbaar te verdedigen op 
vrijdag 6 maart 1998 
des namiddags om 3 30 uur precies 
door 
Gerrit Jan Bergink 
geboren op 13 januari 1959 
te Den Haag 
Promotor Prof dr A F Deutman 
Co-promotor Dr R W M van der Maazen 
Manuscriptcommissie Prof dr Ρ van den Broek 
Prof dr W A J van Daal 
Prof dr С van Weel 
De één kan het niet doen en de ander 
kan het niet laten. 
(F. Swarttouw) 
Aan mijn vader 
Voor Saskia en Gijs 
ISBN 90-9011148-4 
Thesis Catholic University Nijmegen - With ref - With summary in dutch 
Subject heading age-related macular degeneration / radiotherapy / choroidal 
neovasculansation 
The research presented in this thesis was supported by Rotterdamse Vereniging 
Blindenbelangen, Stichting Blindenhulp, Stichting voor Ooglijders, Stichting 
Researchfonds Oogheelkunde Nijmegen, Ciba Vision Ophta, ERGRA, Janssen-
Cilag, Laméns Ootech, Rockmed 
Chapter 
Chapter 
Chapter 
1 
1.1 
1.2 
2 
2.1 
2.2 
2.3 
2 4 
2.5 
2 6 
3 
3.1 
3.2 
3.3 
3.4 
3.5 
Introduction 
General introduction 
Aim of the study 
Age-related macular degeneration 
History 
Epidemiology and risk factors 
Macular anatomy 
Pathophysiology 
Clinical features and diagnosis 
Natural history, treatment and experimental 
therapies 
Radiotherapy 
Background 
Vascular genesis and pathogenesis 
Radiation response of vascular tissue 
Side-effects 
Radiotherapy for subfoveal choroidal 
11 
12 
13 
15 
16 
17 
19 
21 
28 
37 
57 
58 
66 
68 
69 
73 
neovascularisation 
Chapter 4 Radiation therapy for subfoveal choroidal 81 
neovascular membranes in age-related 
macular degeneration. A pilot study. 
Graefe's Arch Clin Exp Ophthalmol 
1994;232:591-598. 
Chapter 5 Radiation therapy for age-related subfoveal 99 
choroidal neovascular membranes. 
A pilot study. 
Doc Ophthalmol 1995;90:67-74. 
Chapter 6 Visual acuity and scar size in eyes with age- 107 
related subfoveal choroidal neovascular 
lesions, 30 months after radiation therapy. 
Doc Ophthalmol 1996,99 61-75 
Chapter 7 A randomized controlled clinical trial on 127 
the efficacy of radiation therapy in 
the control of subfoveal choroidal 
neovascularisation in age-related 
macular degeneration: 
radiation versus observation 
Graefe's Arch Clin Exp Ophthalmol 
1998,in press 
Chapter 8 General discussion 143 
8 1 Discussion and conclusions 144 
8 2 Summary / Samevatting 148 
Nawoord 153 
Curriculum Vitae 155 
ABBREVIATIONS 
AMD 
ARM 
CNV 
DA 
FA 
FAZ 
Gy 
ICG 
MPS 
PED 
RPE 
VA 
SS 
Age-related Macular Degeneration 
Age-related Maculopathy 
Choroidal Neovascularisation 
Disc Area 
Fluorescein Angiography 
Foveal Avascular Zone 
Gray (dose of irradiation) 
Indocyanine Green 
Macular Photocoagulation Study 
Pigment Epithelial Detachment 
Retinal Pigment Epithelium 
Visual Acuity 
Scar Size 

CHAPTER 1 
INTRODUCTION 
1.1 GENERAL INTRODUCTION 
1.2 AIM OF THE STUDY 
Chapter I 
1.1. GENERAL INTRODUCTION 
Age-related maculopathy (ARM), formerly known as senile macular degeneration, 
is the leading cause of irreversible severe loss of central vision in developed 
countries including the U S A and Europe [1] ARM is a clinical diagnosis and 
represents a broad spectrum of diseases of progressive aging and degenerative 
changes in the human macula, including drusen and hyper- or hypopigmentation 
of the retinal pigment epithelium (RPE) ARM occurs in 20 % of individuals over 
65 years of age and the prevalence increases to 35 % in subjects older than 74 
years [1] As older adults become a larger part of our future population, the 
significance of ARM as a public health problem will increase 
The late stages of ARM are called age-related macular degeneration (AMD) 
and can be subdivided into a "dry ' or atrophic form leading to geographic atrophy, 
and a "wet" or exudative form representing choroidal neovasculansation (CNV) in 
the macular area The prevalence of exudative AMD is about 1-2 % in people 
older than 55 years, and increases with age as well [1] 
Patients presenting with drusen and pigment changes can lose central vision 
by two different mechanisms They can develop progressive geographic atrophy of 
the RPE, unassociated with exudation or hemorrhage, with progressive visual loss 
over years and the occurrence of a central scotoma This "dry" or atrophic type of 
AMD occurs in 80-90 % of patients, but accounts for only 5 10 % of severe 
central visual loss defined by a visual acuity (VA) of less than 0 1 The exudative 
stage can develop when new choroidal vessels penetrate Bruch's membrane, 
resulting in CNV, with leakage of fluid and blood under the RPE and the 
neuroretina in the macular area 
Symptoms of CNV in the foveal area are significant loss of central vision, 
metamorphopsia and reduced color vision Although only 10-20 % of patients with 
AMD have the exudative form of the disease, it accounts for 80 90 % of patients 
ending up with a VA less than 0 1 [1,2] The chance that the fellow eye will 
develop CNV as well increases with 5-10 % each year If this happens, the patient 
becomes legally blind Patients with the exudative stage of AMD in both eyes will 
not lose total vision, but with a VA of less than 0 1, they do have lost the 
possibility of reading, recognizing people and performing daily routine life 
activities The deterioration of the VA in case of a subfoveal CNV often happens 
rapidly, in weeks to months, but sometimes takes a slower course over more than 
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three months to one year Knowing that the visual prognosis for AMD patients 
presenting with subfoveal CNV is poor, many attempts have been made to inhibit 
or stop the growth of the CNV in order to maintain central vision 
Current knowledge concerning the natural course and laser therapy options 
for subfoveal CNV has recently been provided by the macular photocoagulation 
study (MPS) group [3] Laser therapy causes local damage to the retina and results 
in impairment of central vision, especially when a subfoveal lesion is treated In 
order to benefit from a smaller central scotoma after 18 months post-treatment, 
patients have to accept an immediate and definite loss of VA [3] However, 
recurrences of CNV in eyes after initially well performed laser treatment occur in 
at least 50% Therefore the majority of patients with the exudative form of 
subfoveal AMD can not be offered any effective therapy at all The aim of any 
treatment of CNV should nof*only be to prevent visual loss but also to keep the 
associated central scotoma as small as possible Low vision aids provide some help 
and always prove more helpful when the scotoma is small 
In the past, some experience with radiation treatment of neovascular age-
related disease has been obtained, but it was never thoroughly investigated nor 
documented In 1990 the departments of Ophthalmology and Radiotherapy of the 
University Hospital Nijmegen were the first to design a pilot study on the effect 
of radiation therapy for subfoveal CNV, with the aim to find the optimum dose 
which would stop the proliferation of CNV membranes, without exceeding the 
tolerance levels of the ocular structures At that time, the idea existed that a 
relatively high radiation dose applied to the macular area would stop the process 
of CNV and would obliterate aberrant newly formed vessels 
1.2. AIM OF THE STUDY 
The objective of this study is to determine whether radiation therapy alters the 
natural course of age-related subfoveal CNV membranes, either by maintaining a 
stable VA and stable central scar size (SS) or by decelerating the decrease in VA 
The next chapters present respectively a review of the disease AMD 
(Chapter 2) and of the principles of radiotherapy (Chapter 3) A pilot study was 
conducted to find a dose-effect relation and to study the efficacy of radiotherapy 
for neovascular AMD The subsequent chapters present the results of this pilot 
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study concerning radiation therapy for age-related subfoveal CNV, compared with 
natural history data These have been published before and are reprinted from the 
journals (Chapter 4,5,6) A randomized clinical trial, based on the results of the 
pilot study, was started in order to evaluate this therapy The results of a the 
randomized trial with an untreated control group are described in Chapter 7 
Finally, Chapter 8 discusses the conclusions and future perspectives concerning this 
experimental therapy 
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2.1 HISTORY OF AMD 
History 
As was indicated m the introduction, in Europe and the U S A visual loss due to 
macular degeneration is a substantial problem because it occurs in about 20 % of 
the population over 55 years of age [1,2,3] Many research groups have been 
working on the pathophysiology, the diagnostic and therapeutic options of this 
disease [1,2,3,4,5,6] The number of patients with AMD in both eyes is growing 
and they can be considered to be legally blind [7] During the last two decades the 
MPS group provided information concerning the natural course and efficacy of 
laser treatment in patients with exudative CNV lesions in AMD [8-18] 
Age-related macular degeneration was first described in 1875 by 
Pachenstecher and Genth in the "Atlas der pathologischen Anatomie des augapfels" 
[19] They described a disc shaped macular lesion However, it was Oeller who 
in 1905 introduced the term "disciform degeneration of the macula" [20] The term 
"senile macular degeneration" has been used, since it was first described as a 
clinical entity by Haab in 1885, to refer to a variety of pigmentary and atrophic 
changes in the macular region [21] 
In 1926 Junius and Kuhnt published a book "Die scheibenförmige Entartung 
der Netzhautmitte (degenerano maculae luteae disciformis)" concerning ten elderly 
patients with disciform subretinal lesions, now known as the end stage of exudative 
macular degeneration [22] They compared their observations with the "retinitis 
circinata" cases described by Fuchs in 1893 [23] Although they recognized the 
influence of vessel leakage on the pathogenesis, the subretinal origin of the disease 
was unknown They concluded "Degenerative Veränderungen in der Netzhaut als 
Folge von Gefaßkrankheit im makularen Ernahrungsbezirk, welche in verschieden 
langen Zeiträumen ablaufen und im Wesentlichen auf den zentralen Neizhautbezirk 
innerhalb der temporalen Gefaßbogen beschrankt bleiben, sind neben progressiven 
Gewebsbildungen variabeler Art der "retinitis circinata" und der "scheibenförmigen 
Erkrankungen der Netzhautmitte" gemeinsam" 
In 1967 Gass first described in a historic monograph, "Pathogenesis of 
disciform detachment of the neuroepithehum", the hypothesis of the development 
of choroidal neovasculansation (CNV) occurring in the macular area because of 
age-related changes in the retinal pigment epithelium (RPE) and Bruch's membrane 
related to drusen [24] Gass postulated "Senile macular degeneration is 
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characterized by mottling of the RPE, drusen formation and loss of the foveal 
reflex Primarily degenerative changes in the chonocapillaris and Bruch's 
membrane are considered with secondary alterations m the RPE and retina Defects 
in Bruch's membrane and neovascular invasion of the sub RPE space from the 
choroid represent complications of senile macular degeneration, which predispose 
the eye to the development of serous and hemorrhagic disciform detachment and 
degeneration of the RPE and retina" However, in 1959, Maumenee had been the 
first who assumed that the blood between the RPE and Bruch's membrane derived 
from the chonocapillaris [25] During the end of the sixties and the beginning of 
the seventies the first results of photocoagulation therapy in early senile macular 
degeneration became available [26,27] Since 1982 until recently, the MPS group 
provided information concerning the natural course of CNV in AMD and data of 
laser photocoagulation treatment applied in these cases [8 18] During the last two 
decades many ophthalmologists obtained experience with laser treatment, to which 
we will return below [26,27] 
2.2 EPIDEMIOLOGY AND RISK FACTORS 
Prevalence 
As was mentioned before, the late stages of ARM are characterized by geographic 
atrophy and neovascular disease, which is also called AMD, and are important 
causes of severe visual impairment in the eldery in industrialized countries [1,2,3] 
Whatever definition or method of diagnosis, all estimates show a strong rise with 
age, and a reasonable overall prevalence for any type of ARM in the age-groups 
65-74 years and 75-84 years is 20 and 35 percent, respectively [29] 
The Framingham Eye Study (USA) noted the presence of AMD in one or 
both eyes in 5 7 % of persons older than 52 years [3] Drusen were noted in 
approximately 25 % of all persons but only 5 7 % had drusen with a decrease in 
VA (< 20/30), defined as AMD The Beaver Dam Eye Study (Wisconsin) 
assessed the prevalence of the features of AMD [1] The prevalence of any AMD, 
including drusen, RPE atrophy and/or hyperpigmentation or exudative disease, was 
19 4 % in subjects between 65 - 75 years and 36 8 % in those older than 74 years 
The Rotterdam Study was the first major European study providing 
population-based data on AMD [29] Comparison with other population-based 
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studies, concerning atrophic and neovascular AMD, was done with the Chesapeake 
Bay Study and the Beaver Dam Eye Study in the United States [30,1]. In the 
Rotterdam study the prevalence of neovascular AMD increases from 0.1 % in 
subjects of 55 to 64 years of age to 7.4 % in persons of 85 years or older [29]. 
The prevalence of atrophic or neovascular AMD in the total population was 1.7%, 
but 11 % in the population older than 85 years and 3 7 % in the age group of 65 -
75 years. In the Beaver Dam Study the prevalence of AMD in the age group of 65 
- 75 years was 7.1 % [1] Hence, comparison between the Rotterdam study, the 
Chesapeake Bay study and the Beaver Dam Eye Study indicates that AMD might 
be less common in the European population. 
A prospective ophthalmic survey of a population in the USA revealed that 
of people aged 45 years or more, 1.2 % have active CNV disease [31]. Recently 
observations have been published that show that in Britain the incidence of visual 
loss caused by AMD has increased in the past 50 years [32]. However, changes 
in diagnosis and detection of this disease could also be an explanation for this 
hypothesis. 
Risk factors 
In the population-based studies many risk factors for the development of AMD 
have been studied [3,29,30]. Familial occurrence of AMD has been observed, 
expecting a genetic component to be involved [33,34,35]. A prospective 
ophthalmological study of 50 spouses and 53 sibling pairs showed a trend towards 
concordance of drusen characteristics between siblings and not between spouses 
[33]. These results support the view that genetic factors play a role in the 
pathogenesis of ARM. 
Beside age, no definite risk factor has been isolated, however conflicting 
results have been found concerning the association between AMD and 
cardiovascular disease, AMD and UV-light exposure and AMD and antioxidant 
status [36,37,38]. Basic research revealed evidence for a possible protective effect 
of antioxidant nutrients like zinc, selenium, vitamine A and vitamine С 
[39,40,41,42] The retina and choroid contain high concentrations of zinc and 
selenium necessary as a cofactor for metalloenzyme systems. These systems are 
involved in the defense against the oxidative threat of the free radical species that 
are generated by light in the retina In general, antioxidant vitamins and zinc have 
a protective effect on light-induced oxidative photoreceptor damage and studies in 
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experimental animals have stimulated interest in the relationship of these 
micronutnents and AMD The Eye Disease-Control Study Group suggested a 
protective effect against neovascular AMD of higher serum anti oxidant levels of 
vitamine С and E, selenium and carotenoids (lutein, zeaxanthin) However at 
present no decided recommendations can be made for taking micronutnent dietary 
supplementation [31] In a study by Vinding et al age, smoking and the daily use 
of hypnotics (sedative drugs) proved to be significantly associated with AMD [38] 
The Rotterdam Study, the Beaver Dam Study and the Chesapeake study all 
found an association between AMD and age and AMD and smoking [29,1,30] 
Besides, the Rotterdam Study provided information concerning the association 
between AMD and atherosclerosis, AMD and women with an early menopause and 
AMD and smoking [43,44,45] Particularly a relation between smoking and the 
neovascular form of AMD was observed current smokers younger than 85 years 
had a 6 6-fold increased risk of neovascular AMD compared to those who had 
never smoked [44] 
Altogether, the concept of genetic predisposition influenced by 
environmental factors, including diet and smoking, in eldery people is reasonable 
[46,47,48,49,50] Currently, there is no convincing evidence that nutritional 
supplementation can affect the development or progression of AMD, however 
smoking is a major risk factor and issue to prevention 
2.3 MACULAR ANATOMY 
The sensory retina (from the photoreceptor cells to the inner limiting membrane) 
vanes in thickness from 0 5 mm in the fovea to 0 2 mm at the equator It is a 
delicate transparent tissue, in the macular area supplied by the superior and inferior 
branches of the central retinal artery In approximately 20 % of the patients a 
cilioretinal artery supplies the papillo-macular area When the RPE is intact, it 
blocks small molecules, like fluorescein, to enter the subretinal space from the 
choriocapillans This is called the outer blood-retinal barrier The inner blood-
retinal barrier is composed of the retinal vascular endothelium The retina receives 
a dual blood supply, one from the choroid, which supplies the RPE and the 
photoreceptors, the other from the retinal vessels, which supply the inner retinal 
layers In a normal macula the choriocapillans supplies the RPE cells and 
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photoreceptors and the outer part of the retina up to the outer plexiform layer of 
nutrients The peculiar structure of the choroidal vascular tree in the macula 
provides this area with the highest rate of blood flow of any tissue in the body [5] 
The specialized structure in the macular region accounts for the predilection of 
certain disease processes to involve this area and for the variety of 
ophthalmoscopic changes [5] 
Histologically, the macula is defined as that portion of the retina that 
contains two ore more layers of ganglion cells, with a high concentration of cones 
and a thick inner limiting membrane Anatomically the macula (macula lutea or 
central retina) is defined as that portion of the posterior retina that contains 
xanthophylhc pigment and two or more layers of ganglion cells The center of the 
normal macula lutea, the yellow spot, is the fovea (Figure 1) 
Figure 1. Postenor pole 
1 The foveola with (diameter 0 35 mm) and the foveal avascular zone (FAZ, 
diameter 0 5 mm) 2 The fovea (1 5 mm diameter) 3 The postenor pole, macular 
area (5 mm diameter) 4 The optic disc (1 5 mm diameter) 
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The fovea with a diameter of 1 5 mm has a central part, the foveola, consisting of 
only cone photoreceptors This area has no capillary bloodvessels and is known as 
the foveal avascular zone (FAZ) However, the anatomic subdivisions of the 
macula are ill defined ophthalmoscopically The center of the macula usually 
appears as a poorly defined zone of slightly greater pigmentation than its maximum 
in the foveolar area 
The macular area is the location of central visual function, emphasized by 
the fact that one third of the nerve fibers of the optic disc originates in this area 
The photoreceptors are highly specialized cells that absorb light Cones are 
responsible for what we consider to be normal vision, that is, fine central vision 
and color vision This is reflected in the great number of second- and third-order 
neurons subserving the cones The photoreceptors depend upon the RPE for 
nourishment and maintenance The RPE is a monolayer of pigmented cells located 
between the neuroretina and Bruch's membrane and is more highly pigmented in 
the central macular area than elsewhere The degree of pigmentation of the RPE 
and the choroid varies according to the pigmentary characteristics of the individual 
In the RPE cytoplasma lipofuscin granules are found, which are residual bodies, 
representing the end product of phagosomal activity Incomplete digestion of 
shedded discs ends up with vesicles with debris called lipofuscin granules [5] 
Bruch's membrane consists of the basement membrane of the RPE on the inside 
and the basement membrane of the chonocapillans on the outside and lies between 
the basal laminae of the RPE and chonocapillans endothelial cells 
In summary, the function of RPE cells consists of phagocytosis of the outer 
segment discs, pumping fluid from the sub-retinal space to the chonocapillans, 
keeping the neuroretina attached, absorbing the light which has passed the 
photoreceptors and scavenging the free radicals formed by the light energy and the 
high oxygen flux in the macular area [2,5] 
2.4 PATHOPHYSIOLOGY 
Introduction 
In patients with ARM and AMD, changes have occurred in the retina, the RPE and 
the chonocapillans [48,49,50,51,52,53] Prominent signs are the development of 
drusen and the hypo- and hyperpigmentation of the RPE in the macular region As 
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was indicated, visual loss in AMD patients results from subretinal 
neovasculansation and detachment of the RPE in the exudative stage and from 
drusen and geographic atrophy in the dry stage 
In older individuals, Bruch's membrane is thickened due to accumulation 
of cellular debris caused by degeneration of the RPE [52,53] The accumulation 
of debris, derived from the RPE, in Bruch's membrane is a progressive 
phenomenon with age, and is seen consistently by the age of 60 years 
Multinucleated giant cells appear to participate in the breakdown of Bruch's 
membrane and, together with diffuse disease of the RPE and changes in the 
physicochemical properties of Bruch's membrane, may provide angiogenic stimuli 
for CNV [51,52] The progressive changes in Bruch's membrane are believed to 
be responsible for the various events It is known that the RPE moves fluid 
outwards from the subretinal space in the direction of the choroid and that the 
conductivity of Bruch's membrane declines with age leading to detachment of the 
RPE When the RPE and subsequently the neuroretina becomes separated from 
Bruch's membrane, functional loss starts with photoreceptor atrophy Loss of 
photoreceptors in the outer neuroretina is a constant association with age [48] 
Below the role of lipofuscin, drusen, the choriocapillans and neovascular changes 
in the development of AMD will be discussed 
Lipofuscin 
Lipofuscin granules are hpid/protein aggregates which are considered to be the life 
long accumulation of lysosomal residual bodies, the end products of photoreceptor 
degeneration [51] With increasing age, as a result of oxidative damage to the 
photoreceptor membrane, human RPE cells accumulate lysosomal lipofuscin, and 
this may be associated with impairment of RPE cell function Lipofuscin deposits 
are also found in Bruch's membrane, possibly associated with the pathogenesis of 
AMD However no correlation has been found between the amount of lipofuscin 
and the development of AMD Accumulation of lipofuscin granules in the RPE is 
not associated with deposition of lipoidal material in Bruch's membrane Both 
processes may represent independent age-related phenomena [51,52,53] 
Drusen 
The presence of drusen, at the level of Bruch's membrane, is considered to be the 
primary indicator of age-related changes [54,55,56,57] Drusen in the macular area 
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were first described by Donders in 1855 [58]. The clinical classification of drusen 
distinguishes between hard, soft and basal laminar drusen [57,59,60]. 
Hard drusen are small yellow-white deposits with a well-demarcated border 
(Figure 2). The RPE cells on top of the hard drusen are hypopigmented. Small 
hard drusen appear in 6.2 % of all eyes with ARM and do not seem to predispose 
to CNV. Soft drusen on the other hand appear on ophthalmoscopy as yellow-white 
spots with indistinct (soft) borders and tend to become confluent leading to 
separation of the RPE from Bruch's membrane [60,61]. The RPE on top of soft 
drusen is often atrophic Finally basal laminar drusen should be regarded as focal 
thickenings of the RPE basement membrane rather than deposition of material 
between this membrane and the inner collagenous layer of Bruch's membrane. 
Dissappearance of drusen has also been recognized and may be related to 
macrophages or multinucleated giant cells [57]. Basal laminar deposits and basal 
linear deposits have histologically been described as extracellular deposits between 
the RPE and its basement membrane. The pathogenesis is unknown and their role 
in the development of AMD is uncertain [62,63]. In a study of 126 patients with 
bilateral drusen cumulative incidence of new drusen lesions proved to be 8.55 % 
at 1 year, 16.37 % at 2 years and 23,52 % at 3 years [57]. 
The appearance of drusen on fluorescein angiography (FA) gives 
information about their nature and prognosis [5] Large confluent drusen which are 
hypofluorescent on FA have a predisposition towards pigment epithelial 
detachments (PED) rather than CNV [48,49,50]. These lipid riche deposits are 
hydrophobic and reduce the conductivity of Bruch's membrane, leading to 
accumulation of fluid in the sub-RPE space. The decline in the hydraulic 
conductivity of the Bruch's membrane-choroid complex with age implies a 
decreased capacity for the exchange of fluid between the choroidal and retinal 
pigment epithelial compartments. Hydrophylic drusen are hyperfluorescent on FA, 
and are at risk for developing CNV [48,49,50] Fluorescence may be dependent 
on the quantity of pigment in the overlying RPE, or more importantly, on the 
presence or absence of fluorescein within drusen material. Frequently, more hard 
drusen will be visible on FA than by ophthalmoscopy. 
Choroidal changes 
It is uncertain whether changes in the choriocapillans are secundary to other 
changes in the macula or whether they in fact are the initiating factors of AMD. 
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There is evidence that the flow of blood in the choroid of AMD affected eyes is 
impaired, but so far neither the nature nor the cause of this impairment has been 
established [64] A combination of increased pulsatihty and decreased velocity of 
the short posterior ciliary arteries is observed in AMD, and can probably be 
interpreted as evidence of increased vascular resistance Impaired choroidal 
perfusion results in degradation of the metabolic transport function of the RPE 
[64] One study suggested that m the dry stages of AMD blood flow is reduced, 
whereas in the exudative stage the ocular blood flow is in the same range as in the 
matched control group [65] However clinical and experimental evidence shows 
that RPE dysfunction in most cases leads to secondary atrophy of the 
choriocapillans 
Neovascularisation 
CNV vessels originate from the choriocapillans and penetrate Bruch's membrane 
either by pre-existing or by newly formed breaks (Figure 2) The new vessels leak 
serous fluid, proteins, lipids and blood under the RPE, eventually leading to RPE 
detachment When the sub-RPE fluid breaks through the RPE, a neurosensory 
retinal detachment occurs When the subretinal hemorrhage becomes invaded with 
fibroblasts, a fibrovascular disciform scar is formed In the development of CNV, 
not only the amount and composition of drusen is important, but also the 
concentration of various growth factors derived from the RPE and the presence of 
macrophages in Bruch's membrane It might be that activated macrophages induce 
the vasoproliferation by the production of growth factors [66,67,68,69,70] On the 
contrary there is also a possibility that RPE cells sometimes release an inhibitor of 
neovascularisation [71] Finally hypoxia has been assumed to be a factor in the 
pathogenesis of ARM and subsequently of exudative AMD [69] 
Histopathologically the initiation of CNV is often associated with the 
presence of a basal laminar deposit, basal linear deposit and soft drusen Large soft 
drusen and focal hyperpigmentation are associated with an increased risk for the 
for the development of CNV [68,69] Ultrastructural features of classic CNV 
include a central core of subfoveal CNV surrounded by a peripheral rim composed 
of fibrin, photoreceptor outer segments and macrophages often accompanied by a 
low-grade chronic inflammatory reaction [72,73,74,75] 
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Figure 2: Localisation of drusen (left) and subretinal choroidal neovasculansation 
(CNV, right) 1 photoreceptor cells 2 RPE cells 3 RPE basement membrane and 
Bruch 's membrane 4 Chonocapillans 5 Drusen 6 CNV located sub-RPE 
Geographic atrophy 
In the end stage of "dry" AMD, only choroidal vessels are visible on 
ophthalmoscopy because of the atrophic changes in the neuroretina, RPE and 
chonocapillans Geographic atrophy is caused by the disappearance of RPE and 
associated photoreceptor cells occunng in the late stages of ARM When the fovea 
is involved, gradual spread of geographic atrophy leads to visual loss In a study 
by Schatz et al it was noticed that areas of atrophy occurred where drusen or 
pigment epithelial detachments had been located before [76] CNV cannot occur 
in a region of geographic atrophy because viable RPE-cells are necessary for the 
development of neovasculansation [76] 
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Conclusions 
One of the first steps in the development of atrophic AMD is the accumulation of 
abnormal material in Bruch's membrane (drusen), very often leading to RPE 
detachment and programmed cell death (apoptosis) of RPE cells As a 
consequence, secundary atrophy of the chonocapillans with increased vascular 
resistance develops, with subsequent cell death in the overlying retina 
[48,49,50,56] The symmetry of drusen m terms of quantity, distribution, and 
chemical composition together with the concept that the form of Bruch's membrane 
deposits determines the nature and magnitude of risk to vision, suggests that the 
two eyes of a patient should behave in a similar manner [50] Also certain genetic 
and environmental factors are part of the aetiology of the disease [48,50] 
Concerning the neovascular stage (Figure 3), it has been proposed that 
diffuse disease of the RPE, changes in the chemical properties of Bruch's 
membrane, drusen and hypoxia of the outer retina may all be interrelated factors 
leading to a release of angiogenic stimuli [50] Although these are interesting 
hypotheses, the mechanism by which CNV in AMD affected eyes is induced is still 
not really understood 
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Figure 3: Multifactorial pathogenesis of neovascular AMD 
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2.5 CLINICAL FEATURES AND DIAGNOSIS 
Clinical features 
The varied manifestations of AMD are subdivided in two categories 
1 Non-neovascular AMD = Atrophic AMD = "dry" AMD 
2 Neovascular AMD = Exudative AMD = "wet" AMD 
Both are often considered separately, however it should be recognized that they are 
merely different clinical end points of a common pathophysiology [8-18,77] On 
the other hand, they have to be distinguished from one another because of the 
difference in visual prognosis 
Atrophic AMD 
The majority (80-90 %) of AMD patients develop geographic atrophy of the 
macula secondary to hypo- or hyperpigmentation of the RPE The disease usually 
presents with decreased central vision in one eye, although the disorder is always 
bilateral, the contralateral eye will often sooner or later experience similar visual 
impairment The majority of patients with "dry" AMD maintain a VA of at least 
0 1 However it accounts for 5-10 % of legal blindness in AMD Geographic 
atrophy corresponds to well delineated areas of chorioretinal atrophy sometimes 
with an increased visibility of choroidal tissue Areas of atrophy appear as 
transmission or "window" defects on FA although staining of areas corresponding 
to geographic atrophy may occur Reading disability is the main complaint of 
patients with maculopathy Therefore the area of eccentric retinal fixation must be 
of sufficient size to allow reading ability by magnifying low vision aids [79,80] 
When the foveola becomes involved in the atrophic process, the patient must shift 
from central to eccentric fixation [80] Visual loss in geographic atrophy is nearly 
always perceived by the patient as a gradual process A possible explanation for 
this is a transitional period during which a patient uses both a foveal and a 
extrafoveal site for fixation The complaint of sudden loss of VA of a patient with 
geographic atrophy should always raise the suspicion of CNV [82,83] 
Neovascular AMD 
The exudative or "wet" stage will develop in 10-20 % of the patients, which means 
that CNV arising from the chonocapillaris penetrates Bruch's membrane and 
proliferates beneath the RPE layer and/or in the subretinal space Subfoveal CNV 
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often leads to rapid loss of central vision within a period of weeks or months 
However, it is not possible to predict how fast the drop in VA occurs as this 
differs between individuals CNV appears clinically as a gray to green subretinal 
lesion often associated with the elevation of the overlying neurosensory retina The 
CNV vessels leak blood, lipid and fluid, which causes further visual impairment 
Only after an investigation including fluorescein photographs, the differentation 
between classic, occult and mixed type CNV can be made [82,83,84,85] The 
natural course is one of fibrotic regression and scarring, with atrophy of the 
overlying retina and underlying RPE Fibrous tissue develops into a "disciform 
scar", which indicates only that the scar is circular in form Functionally, this 
results in extensive central scotoma and a complete loss of central vision and color 
vision A fibrovascular disciform scar may vary in color from white to yellow to 
brown to black, depending upon the degree of RPE-hypertrophy, and is frequently 
associated with subretinal fluid, hemorrhage and lipid 
Diagnosis 
The differential diagnosis of CNV consists of CNV developing before the age of 
50 years and age-related CNV in individuals older than 50 years Visual loss 
associated with CNV m patients younger than 50 years is uncommon and can be 
due to various causes The etiology of CNV in a study of younger patients 
(n = 363) turned out to be high in myopia (62 %), idiopathic (17 %), histoplasmosis 
syndrome (12 %), and angioid streaks (5 %) [86] 
When a patient, older than 55 years, enters the out-patient clinic with complaints 
of reduced VA with metamorphopsia and on ophthalmoscopy signs of AMD, 
further diagnostic procedures are needed, which will be discussed below Moreover 
in case of visible longstanding exudative disease it is important to ask the patient 
for photopsias and visual hallucinations In a study of 100 patients with exudative 
disease, 59 % had a history of seeing flashing light ι e photopsias, and 12 % 
experienced formed visual hallucinations known as Charles Bonnet syndrome [87] 
1. Visual acuity 
In the MPS-group visual acuity (VA) is measured by use of Bailey-lovie charts A 
loss of 3 lines VA represents doubling, and a loss of 6 lines represents quadrupling 
of the minimum angle of resolution, eg, a change from 20/80 (0 25) to 20/160 
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(О 125) and 20/320 (О 0625) Snellen equivalent, respectively Best-corrected VA 
is tested using the Snellen chart Although this mode of testing is subjective and 
represents only a threshold object size about which the patient can make a correct 
judgment, the Snellen chart remains the universal standard of baseline VA because 
of its accuracy, reproducibility and ease of interpretation by both patient and 
clinician [79] The VA for distance, tested with the Snellen chart, is strongly 
associated with the ability to read titles from a large print [79] The Amsler-gnd 
test for metamorphopsia usually follows the VA estimation In case of AMD, the 
patient will notice small scotomas and changes in straight lines 
2. Fluorescein angiography 
As will be clear fluorescein angiography (FA) is the most important diagnostic tool 
when patients present with clinical signs of AMD According to the MPS-group, 
for the last two decades FA has been the mainstay for evaluating the retinal and 
choroidal circulation in general and has proven to be the most important value for 
the diagnosis of CNV The normal FA clearly documents the dual nature of the 
retinal circulation It starts with the filling of the large choroidal vessels and 
choriocapillans the background choroidal fluorescence, followed by that of the 
arteriolar filling phase The choriocapillans vessels are close together and 
normally leak fluorescein resulting in the choroidal flush Fluorescein does not 
normally gain acces to the subsensory retinal space, because of the RPE tight 
junctions (the outer blood-retina barrier) The retinal capillary transit occurs while 
the extravdscular space of the choroid is perfused with dye The retinal capillaries 
do not leak fluorescein normally (the inner blood-retina barrier) Because the two 
separate circulations normally do not overlap and there is avascular tissue ι e the 
outer retina and the RPE between the two, the sensation of depth helps the viewer 
to define the level of pathologic processes [5] 
Abnormalities in the FA can be understood as the presence of too much 
hyperfluorescence, or too little fluorescein hypofluorescence The presentation of 
possible CNV depends on the pattern of hyperfluorescence seen on the FA In the 
past only lesions described as "classic" type of CNV were classified properly 
Until the MPS criteria were developed many terms, like occult CNV and poorly 
demarcated CNV, were used synonymously, while not describing the same 
fluorescein pattern Various studies also noticed difficulties with the detection of 
recurrent CNV after laser photocoagulation were For example, recurrences of 
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CNV after laser treatment can be identified by focal staining and speckled 
hyperfluorescence along the edge of the laser lesion [80] And a comparison 
between clinical examination and FA in detecting recurrent CNV showed the 
identification of a recurrent CNV m 12 % of eyes (n= 137) on the FA in which it 
was not suspected on clinical biomicroscopy [82] Pigment epithelial detachments 
(PED) with a focal hyperfluorescent spot were thought to be associated with a high 
risk of developing CNV, but are now classified according to the MPS-group as 
occult CNV [81] The MPS group presented an international classification of 
angiographic presentation of CNV which will be discussed below[8-18] 
Definition of a classic CNV 
Area of well-demarcated bright hyperfluorescence, often a net of vessels, 
throughout the early phase of the FA, with leakage in the mid and late phase 
frames Vessels of the CNV will be visualized in the early phase but are not 
required to be identified In later phases progressive pooling occurs, which usually 
obscures the boundaries of the CNV (Figure 4) 
Definition of occult CNV 
Type I Fibrovascular pigment epithelial detachment · 
Detectable areas of irregular elevation of the RPE (well- or poorly demarcated) that 
all show stippled hyperfluorescence within 1 to 2 minutes after dye injection, with 
persistent staining or leakage in the late phase after 8 to 10 minutes (Figure 5) 
Type ¡I Late leakage of undetermined source: 
Areas of late phase leakage at the level of the RPE without well-demarcated areas 
of hyperfluorescence discernable m the early phase that can account for the 
leakage 
Definition of mixed CNV 
A combination of classic and occult patterns in one CNV lesion 
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Figure 4. The natural course of a classic CNV (left eye). 
Top left, early phase at presentation (1 DA). Bottom left, late phase at 
presentation. Top right, early phase after 6 months (3.5 DA). Bottom right, late 
phase after 6 months. Note the increase in lesion size and late leakage at 6 months. 
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Figure 5. Occult CNV type 1. Top left, red free of left eye. Bottom left, early 
phase, with stippled hyperfluorescence. Top right, late phase leakage. 
Hence, the terms "classic" and "occult" describe FA patterns. The pattern of CNV 
hyperfluorescence can be described as classic or occult. Well demarcated (well-
defined) and poorly demarcated (poorly-defined) are terms to describe the 
bounderies of a classic or occult lesion (Figure 6). Poorly demarcated bounderies 
refer to bounderies of a lesion in which a portion of the entire interface between 
the lesion and the retina unaffected by any lesion component is not well defined. 
Well demarcated bounderies refer to bounderies of a lesion in which the interface 
between the lesion and the retina which is unaffected by any lesion component is 
well defined. Three features that can obscure the boundaries of CNV are: blood 
that blocks fluorescence through the late phase of the angiogram; elevated blocked 
fluorescence not corresponding to blood to be seen on color photographs 
corresponding to hyperplastic pigment or fibrous tissue; serous PED defined as 
uniform, circular or ovoid distinct detachment of the RPE with early, bright 
hyperfluorescence beneath a smooth dome-shaped elevation of RPE which in the 
late stages increases in intensity in a bright, homogenous, and well demarcated 
pattern. 
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CNV 
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Figure 6. Fluorescein angiographic patterns of CNV. 
In case of subfoveal CNV there are many additional diagnostic modalities. For 
example, indocyanine green (ICG) angiography is often used in case of occult CNV 
[88,89,90,91,92,93,94]. ICG is highly bound to plasma proteins (98 %) and is a 
dye that absorbs and reflects light in the near infrared range permitting 
visualisation of choroidal detail not visualised by FA. Its main clinical application 
has been the ability to identify occult CNV. With the use of ICG angiography it 
is possible to convert occult CNV on FA to classic CNV on ICG in about 40 % 
of the cases. However a contribution to a better VA outcome after laser 
photocoagulation has not been established by this tool [93,94]. It is interesting that 
not all cases of classic CNV diagnosed with FA fluorescence with ICG, which 
suggests that some CNV lesions may leak fluorescein but not protein bound ICG. 
The underlying pathogenesis of ICG hyperfluoresence is not fully understood. An 
understanding of what ICG images represent requires further clinicopathologic 
correlation [93,94]. 
Another new diagnostic development is a combination of ICG angiography and 
microperimetry using the scanning laser ophthalmoscope which allows testing of 
the preferred locus for fixation with direct visualisation of both the test stimuli and 
the fundus [93]. Although the above mentioned techniques are interesting, the main 
diagnostic tool in case of subfoveal age-related CNV remains the FA pattern. 
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2.6 NATURAL HISTORY, TREATMENT AND EXPERIMENTAL 
THERAPIES 
Natural history 
The deterioration of the VA is related to the rate of subfoveal leakage, the amount 
of subfoveal fluid and the subsequent photoreceptor loss The leakage depends, 
among others, on the growth speed of the newly formed subretinal vessels The 
growth rate of CNV in AMD has been estimated to an average of 9-10 urn per day 
[68] However differences in growth rate, amount of leakage and subsequent rate 
of visual loss can be observed The rate of visual loss in a patient presenting with 
subfoveal CNV remains unpredictable but is partly dependent on the type of CNV 
(classic, mixed or occult) at presentation The natural course of subfoveal CNV is 
charatensed on FA by an increase in size of the membrane and an increase in late 
phase leakage over time (Figure 4 and 7) 
There was no consistent approach in describing fluorescein patterns in case of CNV 
before the MPS definitions The results of the following studies cannot always be 
fully compared with each other 
A study by Singerman et al determined the poor natural history of occult 
subfoveal CNV with a PED in AMD At one year follow-up of 55 eyes, 65 % had 
a VA less than 0 1 and 26 % even less than 0 05, 94 % of the patients developed 
a final VA of 0 1 or worse [99] Another study of the natural course of occult 
CNV by Bressler et al showed a severe decline in VA in 63 % of eyes after 12 
months [96] The natural course of occult CNV was also determined in a 
prospective study New lesions occurred in 50 6 % of the eyes (n = 79) and the 
incidence of visual loss by 2 lines or more was 33 % after 2 years [100] 
Spontaneous regression of CNVs is extremely rare and occurs in less than 1 % of 
cases [101] 
Soubrane et al described the poor natural course of CNV with subretinal 
hemorrhage [102] Patients with extensive subfoveal hemorrhages in occult CNV 
in AMD and without laser treatment will develop severe visual loss in 80 % of the 
eyes (n = 68) with a mean final VA of only 0 02 [103] A retrospective review 
of data of subfoveal hemorrhage in AMD revealed a progressive loss of VA from 
baseline in most eyes after 3 years After 6 months and 12 months, the VA 
decreased in 75 % and 69 % respectively [104] 
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Figure 7. Natural course of mixed CNV. 
Top left, red free at presentation. Bottom left, late phase at presentation. Top 
right, red free after 6 months. Bottom right, late phase after 6 months. Note an 
increase in lesion size and late phase leakage. 
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Detailed information concerning the natural course of classic subfoveal CNV, 
eligible for laser treatment, is provided by the MPS-group [8-18] Only subfoveal 
lesions smaller than 3 5 DA were included because, in case of treatment, large 
lesions would leave too few pen foveal photoreceptors unaffected to allow for 
useful vision The VA after 3 and 12 months follow-up, in untreated eyes with a 
small CNV (DA 1 or less) and an initially VA of 0 2 or better, declined to 0 16 
or less in 58 % and 78 % respectively [12] For lesions with an initial medium size 
( > 1 DA and <2 DA), a decline in VA after 3 and 12 months was found in 67 % 
and 79 % respectively [12] In 1986 the MPS-group also started a randomised trial 
of laser treatment versus no treatment in classic subfoveal CNV The change in 
visual acuity in the no-treatment group from the initial visit to 3 and 24 months 
was estimated After three months of follow-up respectively 52 2 % (n = 178), and 
after 24 months 82 1 % (n= 112) lost more than 2 lines of VA 
Other results concerning the natural history of classic and occult subfoveal 
CNV became available during a multi-center randomised study on the effect of 
Interferon in cases of AMD [128] In a total group of 112 eyes, 58 % of classic 
CNV, 35 % of occult CNV and 37 % of mixed CNV, lost 3 or more lines of VA 
at 1 year follow-up Concerning the size of the CNV it was concluded that the area 
in disc diameters doubled in six months in the classic CNV group and doubled in 
12 months in the occult and the mixed group In the classic group the size of the 
CNV did not increase between 6 and 12 months follow up [128] 
The prognosis of the fellow eyes of patients with one eye affected with 
CNV secondary to AMD depends on the presence of 5 or more drusen, focal 
hyperpigmentation and definite systemic hypertension Estimated five year 
incidence rates ranged from 7 % for the subgroup of fellow eyes with no risk 
factors to 87 % for those with all 3 risk factors [129] 
In conclusion, when a CNV is initially present within the avascular foveal 
zone the VA will become 0 1 or worse in 70-80 % of the affected eyes within 18 
months [2,94] Visual loss is often rapid and foveal involvement at presentation is 
seen in 90 % of cases [2,94] 
Treatment 
During the last two decades, if patients with neovascular AMD were treated, they 
have mostly received laser treatment, although several experimental modalities 
have been applied as well [8-18] All these types of therapy will be discussed in 
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this paragraph, apart from the application of radiation therapy, which is the subject 
of the following chapters With regard to laser treatment, no differences have been 
found between the efficacy of Argon red or green, yellow Dye or Diode laser 
wavelengths in treating CNV In the past very often laser photocoagulation of CNV 
was incomplete, because the occult part was not treated In general, temporary 
regression of an untreated part of CNV can occur within 3 months after laser 
therapy, however activation or relapse often develops after this period (personal 
communication Bressier NM) 
The pattern of visual loss for new subfoveal lesions is influenced by the 
initial lesion size and the initial VA Laser photocoagulation therapy is only 
recommanded for small CNV lesions ( < 1 DA) with a poor VA (0 1 or less) at 
presentation The patient must accept an immediate decrease in VA, but after 2 
years his VA will be better compared with no treatment, because of the smaller 
central scotoma An ultimate benefit of only one Snellen line was seen after 18 
months of follow-up in laser treated patients compared with a control group 
Treated eyes experiences an immediate decrease in VA (3 lines on average) so the 
patient and the ophthalmologist must be thoroughly prepared 
An analysis from the patient's perspective by Bernstein et al revealed a 
strong preverence for laser intervention by patients with eligible subfoveal CNV, 
despite this risk of immediate visual loss [105] However, opinions differ on the 
question whether it is preferable to have a marginal long-term benefit, starting 18 
months later, at the cost of a significant deterioration immediately after treatment, 
rather than this impairment developing over a period of years 
In eyes with subfoveal CNV, foveal-sparing laser photocoagulation has been 
proposed as an alternative modality [105] In a pilot study stabilisation of the pre-
treatment VA in 60 % of eyes (n=40) after one year has been noticed after scatter 
photocoagulation of subfoveal CNV [107] Comparable results have been noted by 
Coscas et al after perifoveal laser treatment for age-related subfoveal AMD [108] 
However recurrences of a CNV after laser therapy occur unfortunately in about 
50 % of initially well treated eyes A study by Soubrane et al has shown that in 
case of occult CNV, laser therapy results in a worse outcome in terms of final VA 
when compared to no treatment [104] 
A large proportion of patients (87 %) with CNV, occult CNV in particular, 
do not meet MPS guidelines and therefore only 13 % of the patients with classic 
well-defined CNV appear eligible for laser treatment [77] 
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Experimental therapies 
ICG-guided laser treatment 
ICG angiography is a new experimental diagnostic procedure for visualizing normal 
and abnormal choroidal blood vessels However the fact that treatment to areas of 
hyperfluorescence on FA can be beneficial does not mean that treatment to areas 
of hyperfluorescence on ICG should be beneficial as well The gold standard for 
imaging CNV remains FA and it has been shown that no patient is being deprived 
by not having access to ICG angiography [109,110] 
Submacular surgery 
Many reports have been published concerning the removal of subfoveal neovascular 
membranes [113-119] Preliminary clinical experience with the surgical removal 
of subfoveal CNV suggests that central vision may be restored in eyes with CNV 
due to presumed ocular histoplasmosis syndrome and to idiopathic causes [115] 
However disappointing results have been reported concerning the results of surgical 
removal of subfoveal CNV in AMD This is probably due to the multiplicity of 
ingrowth sites of CNV in AMD and, consequently, the inevitable removal of vital 
RPE and often choriocapillans during surgery Yet, it is still unclear at which point 
of the natural course the indication for surgery should be given and which method 
yields the best results, a clinical trial evaluating submacular surgery versus 
observation of subfoveal CNV has been planned An experimental surgical 
procedure introduced by Machemer, macular translocation, did result m improved 
monocular vision [120] 
RPE transplantation 
An experimental approach of transplanting fetal RPE-cells under the macula 
resulted in survival of these cells for as long as 3 months [121] In cases of 
exudative AMD no positive effect on the visual loss was observed 
Photodynamic therapy and benzoporphynn-hpoprotein 
The application of photodynamic therapy, using lipoprotein-dehvered 
benzoporphynn derivate mono-acid photosensitizing dye administered 
intravenously, resulted in the closure of experimental CNV's m monkeys [122] 
A multicenter clinical trial has been started comparing this type of therapy with the 
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application of diode laser and benzoporphynn derivate and placebo in patients with 
mixed type subfoveal CNV in AMD 
Pharmacologic therapy 
1. Interferon a 
A prospective randomized study has recently been ended because Interferon-a-2a 
provided no benefit as a treatment for CNV in AMD Although pilot studies 
demonstrated a stabilisation of CNV's during this therapy [123] 
2. Thalidomide 
As a potent inhibitor of corneal neovasculansation in mice, Thalidomide is at 
present used in small pilot studies for patients with neovascular AMD [128] 
3. Anti-vascular endothelial growth factor 
So far, there has only been gained experience with the administration of 
monoclonal antibodies inhibiting vascular endothelial growth factor in a monkey 
model [128] 
Treatment of drusen 
Knowing that hyperfluorescent soft drusen are at risk for developing exudative 
AMD, laser therapy is performed in an attempt to alter the natural course [124-
126] In a study by Figueroa et al drusen dissapeared within 3 5 months after laser 
therapy, without complications [125] It is thought that laser stimulates 
macrophages and other phagocytic cells that can cause drusen to disappear and 
that it may destroy deteriorated RPE cells However, it remains questionable if the 
treatment of drusen indeed results in a reduced risk of CNV development 
Vitamins and Zinc 
The National Eye Institute in the USA has recently begun a multi-year study of the 
clinical course and prognosis of AMD including a trial component to evaluate the 
effect of vitamins, carotenoids and mineral supplements on the development of 
AMD [128] 
Experimental treatment of subretinal new vessels using hyperthermia is under 
investigation (personal communication) 
In conclusion, it is increasingly evident that laser treatment nor any of the 
above mentioned therapies will significantly reduce the severe visual loss 
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experienced by most patients with this neo vascular macular disease. Again it is 
important to emphasize that AMD virtually never leads to total blindness and that, 
often with the use of low-vision aids, even the patient affected in both eyes remains 
visual function [109,110]. In patients with central scotoma an eccentric retinal 
fixation area of sufficient size is necessary to regain reading ability by magnifying 
visual aids i.e. low-vision aids. Still, the social cost of this visual handicap is high 
and it is important to move forward in the management of AMD, especially since 
it is likely that in the future, as the population ages, ophthalmologists will be 
examining increasing numbers of these patients The knowledge gained by studying 
the influence of radiation therapy on AMD will be important, independently of the 
outcome [127]. 
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3.1 BACKGROUND 
Introduction 
Tissue damage by ionising radiation with electromagnetic photons (gamma- and 
roentgen or X-rays) results from energy absorption of the various cells [1,2,3,4] 
After irradiation of biological tissue three phases can be observed First the 
physical phase consists of interactions between charged particles and the atoms of 
which the tissue is composed The chemical phase (second phase) describes the 
period in which the damaged atoms and molecules react with other cellular 
components leading to free radicals Free radicals interact with macromolecules 
within the cell to produce molecular changes, mainly in the chromosomal DNA 
As a result irradiation acts on the replicative mechanism of cells The third phase, 
the biological phase, begins with repair of damaged DNA and death of stem cells 
as early reactions ending up with late reactions including radiation carcinogenesis 
Damaged DNA is responsible for the loss of the dividing capacity of the cell, 
although the cell may remain its normal biochemical function and normal 
morphological structure The survival of a sterilised cell depends on its 
proliferative activity, because the damage only becomes visible after the next cell 
division 
Tissues 
A tissue consists of a group of differentiated cells with a specific metabolic 
function Specialised cell types with a specific function can cooperate in an organ, 
like for example liver cells An increase m the amount of cells is not only 
necessary for tissue growth during development, but also to replace the loss of 
dead cells or cells lost during differentation Tissues can be catagonzed according 
to their cell dividing activity in either type-Η (hierarchical) or type F (flexible) 
tissues [1,2,4,5] In type-Η tissues, cell populations for cell renewal and function 
are separated in different compartments (Figure 1 a) For example in the skin, stem 
cells divide and become either proliferating cells or new stem cells The fast 
dividing proliferating cells eventually mature into differentiating transit cells and 
mature postmitotic functional epithelial cells Liver on the other hand is an 
example of a type-F tissue because it has functional cells that are also capable of 
self renewal (Figure 1 b) F-type tissues have a less recognisable separation into 
different compartments and functional cells maintain their capacity of proliferation 
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Stem cells *- Stem cells (self-renewing) -» Precursors -» Mature cells 
Figure 1 a. Hierarchical tissues Tissues with a recognisable separation between 
the stemcell compartment, an amplification compartment and a post-mitotic 
compartment of mature functional cells 
Stem cells «* Mature functional cells 
Figure 1 b. Flexible tissues Tissues without a recognisable separation between 
these compartments Functional cells have the capacity of renewal 
Radiation effects 
Between the various cell types a difference exists in cell survival after a radiation 
dose After irradiation cells may not be affected at all, may be affected but their 
damage can be completely repaired or are affected and show cell death either 
mitotic or apoptotic Often cells have the possibility to repair the radiation damage 
and maintain their biochemical function, but have lost the possibility to divide 
These cells are sterilised and biologically death, because they cannot proliferate 
anymore Mitotic death occurs when the sterilised cell attempts to divide In case 
of fast dividing tissues, an early radiation effect is noticed, while slow dividing 
tissues express radiation damage after a longer lag time [1,2,3,4,5] 
Apoptosis is a physiological mechanism of cell death that is genetically 
regulated and contributes to the balance between cell growth, differentiation and 
maintenance of normal tissues [4,5] Interphase death occurs unrelated to the cell 
cycle in irradiated nonproliferating cells by apoptosis, a natural programmed cell 
death, necessary for the elimination of genetic abnormalities [1,2,4,5] 
Radiation may lead to single-strand DNA breaks and double-strand DNA 
breaks The number of lesions induced by radiation in DNA is greater than those 
that lead to cell killing Cells are able to repair radiation-induced single-stranded 
DNA breaks Breaks in double strand DNA is the most common type of radiation 
lesions that lead to cell death Residual DNA double-stranded breaks which the cell 
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fails to repair are regarded as those that lead to radiation induced cell death 
Several studies have suggested that radiation damage to the least active regions of 
the genome, such as those which reside within heterochromatin, may be the most 
critical for cell survival [1,2,3,4,5,6,7,8] It is hypothesized that DNA involved 
m synthesis is more accessible to repair enzymes than inactive regions located 
within tightly bound heterochromatin or mitotic chromosomes The human retinal 
vascular endothelial cells are distinctively heterochromatic, with the bulk of the 
chromatin around the nuclear envelope, resulting in much more radiosensivity than 
for example the inner retinal neurones whose nuclei are highly euchromatic It is 
known that the highly heterochromatic nuclei of rat photoreceptor cells are 
exquisitely sensitive to ionising radiation compared to those of primates that are 
more euchromatic [3,7,8,9,10] 
Tissue response 
After irradiation, fast dividing tissues will express radiation damage within days 
to weeks Therefore these tissues are called acute responding tissue Damage 
occurs when the functional cell compartment is not replaced by new cells because 
of radiation induced cell death of the proliferating cells The natural loss of 
functional cells is not compensated for Tissues depending for their integrity on 
continuous cell proliferation will be damaged early by irradiation [1,2,4,5] Early 
damage (from weeks to months) may be followed by late types of damage, often 
with a vascular basis In the skin acute epidermal reactions may be followed by late 
vascular reactions, like fibrosis and atrophy Slow dividing tissues, for example 
vascular endothelial cells, may retain latent radiation damage until its expression 
at mitosis These tissues are called late responding tissues In Η-type tissues, the 
tune between irradiation and tissue response is dose-independent and related to the 
life-span of the functional cells The rate of recovery, however, is dose-dependent 
and related to the number of surviving stem cells 
Principles of radiobiology: the 5 R's. 
The biological factors that influence the response of tissue to fractionated 
radiotherapy are known as the 5 R's of radiobiology [1,2,4,5] The 5 R's of 
radiobiology affect both normal tissue and malignant cells 
1 Radiosensitivity 
There is a difference by nature between various types of cells and tissues 
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concerning the susceptibility of radiation known as the intrinsic radiosensitivity A 
certain dose damages more cells in sensitive tissues than the same dose does in 
resistant tissues For example malignant lymphoma cells are very radiosensitive, 
while glioblastoma cells are radioresistant 
2 Repair capacity 
Cells may repair radiation damage when they are given time to do so, resulting in 
maintainance of the cell function and cell proliferation The amount of sublethal 
damage depends on the tissue type and the radiation dose and can accumulate and 
become lethal The capability of repair of sublethal damage strongly differs 
between various cell types, but most damage is repairable if the cell is left for 
hours before the next dose is administered If this phenomena is more pronounced 
in normal than in target tissue, fractionated irradiation leads to a better therapeutic 
effect with less side effects 
3 Repopulation 
As a reaction to cell death caused by irradiation, clonogenic stem cells start 
accelerated proliferation to produce new cells rapidly A rest period during 
fractionated radiotherapy is accompanied by repopulation of target cells and 
surrounding tissue Cells that survive irradiation proliferate and thus increase the 
number of cells that must be killed In case of fast dividing cells, repopulation 
during the time between two fractions, results in a loss of radiation effect 
4 Reoxygenation 
Radiation kills viable oxic cells preferentially and anoxic cells may be rescued, 
resulting in more hypoxic cells surviving after a dose of radiation Because death 
oxic cells disappear, a decrease in distance between hypoxic cells and capillaries 
occurs with an increase of oxygen flux towards hypoxic cells Fractionated 
irradiation results in a smaller proportion of surviving hypoxic cells 
Reoxygenation means that fractionated radiation leads to a shift of cells out of the 
hypoxic cell compartment towards the well oxygenated group, resulting in a higher 
irradiation effect 
5 Redistribution 
In general, the effect of radiation on a cell is low during the S-phase (= DNA 
synthesis) of the cell-cycle and the highest just before mitosis (= M-phase) Cells 
in M-phase will be more damaged resulting in a relative increase of cells in S-
phase Cells that survive a first dose of radiation will tend to be in a resistant phase 
(S-phase) of the cell cycle and within a few hours they may progress into a more 
61 
Chapter 3 
sensitive phase (M-phase) This means cells synchronise and reach the M-phase at 
the same time This phenomena is called redistribution The time between fractions 
can be influenced to profit of this redistribution 
Physical factors that influence the radiation sensitivity 
Clinically the main factors that influence the development of radiation damage are 
1 Total radiation dose and fraction size 
The radiation dose is the kinetic energy released to material and is expressed in 
Gray [1 Gray (Gy) = 1 joule/kg = 100 rad] 
It is important to recognize that comparison of a total radiation dose between two 
types of fractionated treatment is dependent on the biological effect [1,2,4,5] 
Considering a tissue with a specific radiosensitivity, it will have for example 10 
stem cells left after a dose of 10 Gy in one fraction, while after 10 Gy in two 
fractions of 5 Gy, the amount of stem cells, capable of growth, will be 15 The 
same total dose (10 Gy) leads to a difference in biological effect (10 versus 15 
stem cells left) In general, a dose given in one fraction leads to less surviving cells 
than the same dose given in two or more fractions, e g fractionation allows a 
higher dose to be administered 
The linear-quadratic model, LQ model, is developed for comparing the 
relation between the dose per fraction, the total dose and the biological effect on 
tissue [4,5] In general, the surviving fraction of target cells decreases with an 
increase of the administered radiation dose The surviving fraction (SF) after a 
dose per fraction d is given by SF= exp(-ad-ßd2) The α-component (linear 
component) determines the cell survival curve after low dose irradiation, but at 
higher dose the quadratic ß-component is the most important A cell survival curve 
is the relation between the dose and the fraction of surviving colony forming cells 
The relation between the radiation dose and the fraction of surviving cells is shown 
in figure 2 Clonogenic cells are cells that are able to form in vitro colonies 
exceeding 50 cells (representing 5-6 divisions) The shape of the curve depends, 
among others, on the cell type, the radiation type and the time between fractions 
Cell survival curves show lower efficacy of killing at lower doses, before 
exponential cell killing is demonstrated at higher doses, so they are characterized 
by a "shoulder" on a semi-logantmic scale 
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Figure 2. Cell surviving curve (black line) Relation between the radiation dose 
and the fraction of surviving cells The a-component predominates at low dose and 
the ß-component predominates at higher dose Dose in which the a-contnbution 
equals the β contribution α=β X-axis Radiation dose (Gy), Y-axis Surviving 
cell fraction 
The α/β ratio, experimentally obtained for the various tissues, describes the shape 
of the fractionation response, a low α/ß ratio (1-4 Gy) for example in liver and 
bloodvessels, is characteristic of late-responding tissue (lag time= 0 5-5 years) 
A low α/β ratio corresponds to a cell survival curve with a strong quadratic 
component and steep curve because of a relative large β influence Fractionated 
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irradiation leads in case of a low α/ß ratio, to less radiation damage and a greater 
repair Repair of sublethal damage can be measured by the increase in dose 
necessary to obtain biologically the same effect A small α/ß ratio indicates a large 
susceptibility to fractionation and a large repair capacity From clinical experience 
it is known that a change in the number of fractions, with a subsequent change in 
the dose per fraction, has no effect on early reactions, however radiotherapy with 
fewer larger fractions give an increase in late effects Hence, the sensitivity to 
large fraction sizes is much higher for late-responding tissues than for early-
responding tissues 
The α/ß ratio of normal tissue is related to the time between irradiation and the 
moment of tissue reaction (Figure 3) Early responding tissues, between 3-9 weeks, 
are characterised a high α/ß ratio (10 Gy), like skin, with actively proliferating 
stem cells 
latency 
time 
fractionation 
susceptibility 
sensitivity 
Early reactions 
between 3-9 weeks 
Low 
α/ß = 10-25 Gy 
Late reactions 
between 0 5-5 years 
High 
α/ß = 1-4 Gy 
Figure 3. Characteristics of early and late responding tissues 
The effect of fraction size and total dose will be illustrated in the following 
example The biological effect of a total dose of 24 Gy administered in 12 fractions 
of 2 Gy is not the same as a total dose of 24 Gy in 4 fractions of 6 Gy For 
example Current treatment for subfoveal CNV is 4 fractions of 6 Gy per day 
resulting in a total dose of 24 Gy How many fractions of 2 Gy give the same 
biological effect, presumed an α/ß ratio of 2 Gy 9 
Formulas 
LQ-model RE = 1 + d 
a/ß(2,5) 
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Dtol = ETD/RE 
RE = relative effectiveness per dose 
d = dose per fraction 
Dtol = tolerance dose with dose per fraction d 
ETD = extrapolated total dose = extrapolated tolerance dose 
α/ß ratio = specific for each tissue 
Dtol = 6 Gy 4 = 24 Gy 
RE = 1 + 6 / 2 = 4 
ETD = 2 4 4 = 96 Gy 
d = 2 RE = 1 + 2/2 = 2 
Dtol = 96/2 = 48 Gy 
48 / 2 = 24 fractions 
In conclusion 4 fractions of 6 Gy per day causes more or less the same biological 
effect of 24 conventional fractions of 2 Gy, according to the LQ-model with a 
presumed α/ß ratio of 2 Gy 
2 Time factor 
The overall treatment time, the time between the first and last fraction, during 
radiotherapy is of importance mainly for acute reactions, rather than for late 
reactions However the tune factor is rather complex and depends on the dose per 
fraction, the interfraction interval and on the tissue type In general, a total dose 
administered in 6 weeks is more effective than the same dose given in 12 weeks 
The underlying phenomenon responsible for this observation is repopulation 
Surviving cells start to divide when the time between 2 fractions is longer than 
approximately 24 hours This results in an increased cell number, needing an 
increase in total dose For late reactions in normal tissues, no appreciable 
difference can be found between a short or a longer treatment time 
3 The irradiated volume 
The size of the radiation field is responsible for the volume-effect In general the 
tissue tolerance decreases with increasing treatment volume Midena et al 
concluded that radiation retinopathy has a higher incidence and a lower latent time 
when the whole eye is irradiated including the peripheral chonoretina [12] 
4 Concurrent chemotherapy 
Combined radiation and chemotherapy can result in retinal damage and remarkable 
vasculopathy after a total dose, which under normal circumstances (without 
chemotherapy), would not be harmfull 
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5 Systemic conditions 
There is a synergistic association between ionising radiation and the diabetic state 
Radiation vasculopathy tends to occur earlier and to be more severe in diabetes 
patients Radiation retinopathy and diabetic retinopathy are both occlusive 
micrangiopathic diseases and therefore may have a synergistic effect Radiation 
retinopathy occurs more frequently in diabetes patients compared with controls 
Thus it is clear that diabetes as well as collagen diseases negatively infuence the 
effect of irradiation of the eye [1,2,3,4,5,10,11,12,13] 
3.2 VASCULAR GENESIS AND PATHOGENESIS 
The term angiogenesis describes the generation of new blood capillaries from 
preexisting vessels which occur in both normal situations, for example wound 
healing, and in pathological situations like in neovascular AMD [14,15] The 
normal architecture of human capillaries consists of endothelial cells with pericytes 
The morphologic steps occurring during capillary neovasculansation in rabbit 
corneae include degradation of the preexisting vessel basement membrane by 
proteolytic enzymes Stimulated endothelial cells migrate towards the angiogenic 
stimulus and begin to proliferate Capillary lumen is created by curving of 
endothelial cells and after new basement membrane formation blood flow begins 
[14,15] 
Histological examination with electron microscopy of human eyes showed 
an endothelial cell sprout, originating from the chonocapillaris, passing through a 
narrow gap in Bruch's membrane in 6 eyes with exudative AMD [16] The tip of 
the endothelial sprout was surrounded by enlarged pericytes and the endothelial 
cells were thickened and irregular This supports the hypothesis that pericyte 
mobilisation may accompany endothelial cell migration in angiogenesis in 
intrachoroidal new vessel formation [16] 
Angiogenesis is required for tissue repair in the adult but is also responsible 
for a variety of pathologic disorders Studies in experimental oncology have shown 
that angiogenesis is necessary for primary tumour growth, progression and 
metastasis [15] Tumours are, in general, angiogenesis-dependent diseases This 
means that angiogenesis is necessary for primary tumor growth, progression and 
metastasis and that its inhibition may lead to tumor remission [15] It has been 
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proven that many bioactive products, including vascular endothelial growth factor 
(VEGF), fibroblast growth factor (FGF), transforming growth factor-beta (TGF-ß), 
macrophages and endothelin-1 promote angiogenesis in various models, but the 
relationship between this activity and the regulation of blood vessel growth is not 
fully understood [17,18,19]. Endothelial cells not only respond to tumour secreted 
growth factors, but also actively stimulate tumour cell proliferation through 
production of these soluble growth factors [15,17,18]. Angiogenesis inhibitors, 
suppressing neovascularisation of tumors, have an important role in tumor 
remission [17]. Anti-angiogenic drugs like Interferons, Thalidomide and Tamoxifen 
are inhibitors of endothelial cell proliferation. 
In ophthalmology, intra-ocular neovascularisation is observed in patients 
with for example diabetes mellitus, central retinal vein occlusions and exudative 
macular degeneration. Retinal neovascularisation occurs after the release of 
angiogenic factors by the ischaemic retina [14,15]. Elevations of VEGF levels in 
the vitreous humor of eyes with proliferative retinopathy have been described 
[14,15,17]. That VEGF levels correlate with ocular angiogenesis is supported by 
the report that intra-ocular administration of anti-VEGF antibodies inhibits the iris 
neovascularisation following central retinal vein occlusion in a primate model [17]. 
Immunohistochemical localisation of VEGF in surgically resected neovascular 
membranes raises the possibility that it is also a mediator of neovascularisation in 
exudative AMD [17 ]. It is speculated that the normal retinal glial cells and retinal 
pigment epithelial cells produce VEGF, necessary for maintaining the normal 
structure and function of retinal capillaries and choriocapillaris [14,17]. 
The normal regulation of angiogenesis is influenced by stimulating and 
inhibiting factors, but how angiogenic factors are released and influenced is largely 
unknown. Although the pathogenesis of choroidal neovascularisation is still under 
investigation, macrophages and pigment epithelial cells are thought to play a role 
during angiogenesis by releasing factors, including VEGF. However, the 
endothelial cells of the neovascular membrane itself may synthesize VEGF 
[14,17,19]. 
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3.3 RADIATION RESPONSE OF VASCULAR TISSUE 
Investigations concerning endothelial cell survival in vitro have shown the large 
radiosensitivity of endothelial cells compared with other cell types, for example 
pericytes, constituting the vessel wall [3,4] After irradiation of endothelial cells 
it is important to know the relative number of endothelial cells required to preserve 
tissue function On the basis of cell survival determination it is estimated that with 
only one in ten endothelial cells surviving, the tissue may survive [4] The 
remaining endothelial cells have been shown to spread and to cover a larger area 
of the vessel wall [4] 
Archer and co-workers studied the earliest microvascular changes after a 
wide range of single dosis radiation (2 20 Gy) in the retinae of the Lister rat, 
which vasculature is comparable to the human [6,8] The changes were most 
evident between 6 and 12 months after exposure to 15-20 Gy, and the earliest 
observable pathology was elongation of the capillary endothelial cell nuclei and 
narrowing of the capillary lumen More affected vessels showed endothelial cell 
loss and capillary closure The retinal pigment epithelium and choroidal circulation 
were less radiosensitive 
Morphological changes occur chronologically in human capillaries after 
irradiation with a single dose of 8 7 Gy [2] Within hours vasodilatation and loss 
of vasomotion occurs, with swelling and vacuolation of the cytoplasm of 
endothelial cells Clusters of platelets attach to damaged endothelial cell sites and 
interrupt the blood flow in some vessels Within weeks, loss of endothelial nuclei 
can be observed, with a reduction in the number and length of the capillaries and 
occlusive changes Late effects after months to years are teleangiectasia and 
proliferation of endothelial cells and fibrosis [1,2,3,6,8] 
During the natural course of eyes with subfoveal CNV, fibrovascular scar 
development shows similarities with the normal wound healing process In general, 
acute inflammation, invasion with polymorphonuclear leucocytes transforming to 
macrophages, fibroblasts and the newly formed capillaries are all part of the wound 
healing process In a study determining the effect of irradiation of ocular wounds, 
suppressing of mononuclear cell division was noticed after local wound irradiation 
[9] Furthermore, it was concluded that irradiation of ocular wounds affected 
inflammation both quahtively and quantitively and limited intraocular cellular 
proliferation [9] 
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3.4 SIDE-EFFECTS 
Introduction 
As the lag time of response of normal tissues to therapeutic radiation exposure 
varies from one type of tissue to another, irradiation with X-rays can result in the 
occurrence of acute, subacute and/or late effects. All components of the eye can 
be affected by radiation, but it is clear that the various tissues have different 
radiosensitivities. The mature retina is relatively resistant to clinical doses of 
radiation because of its stable population of nerve cells [3]. One should be aware 
that there is a tenfold difference in dose between the cataract threshold and the 
dose required to damage the retina [27]. 
Despite improvements in radiotherapeutic methods such as shielding and lens-
sparing techniques, it is often difficult to treat the target-tissue without irradiating 
the lens. The eye and ocular adnexa are vulnerable to ionising radiation with a 
different susceptibility of the various tissues. The late effects of irradiation of the 
eye are known from patients treated for ocular disease but also from those treated 
for diseases of the central nervous system and of the ear-nose-throat region. 
Side-effects 
Acute and late effects of radiation on the eye and ocular adnexa, and tolerance 
levels of the various ocular structures are well known from many studies 
[3,6,15,10,11,12]. However, it is difficult to evaluate the literature data on ocular 
radiation morbidity because of differences in treatment planning and problems to 
assess the exact radiation dose actually delivered to the eye after for example 
treating the central nervous system, orbit or para-nasal sinuses. Recently, a 
consensus conference was held on the radiation-induced pathophysiological and 
clinical changes of the various ocular structures as well as dose-response data and 
management of ocular complications [13]. When establishing dose-effect data, it 
is important to distinguish between a single or a few large radiation fractions 
versus multiple small conventional fractions. A conventional fraction size of 2.0 
Gy/day is commonly considered a standard fraction. Larger fractions are generally 
more damaging than the same dose delivered with conventional irradiation [3] (see 
page 65; the LQ-model). 
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Ocular adnexa and anterior segment 
Acute reactions following radiotherapy include hyperaemia of the conjunctiva and 
erythema beginning after a few days and resolving within 2 to 4 weeks Eyelids 
react to radiation similar to skin, with erythema after 30 40 Gy in conventional 
fractions, which is almost always self-limiting Permanent epilation of eyelashes 
is observed after a radiation dose in excess of 50 Gy in conventional fractions 
Conjunctivitis may develop during radiation in the range of 50 Gy Punctate 
keratitis, a superficial lesion of the cornea epithelium, can occur after doses with 
30-50 Gy in 4 weeks 
A severe late complication is the so-called "dry-eye syndrome" Concerning the 
lacrimal gland the majority of patients tolerate doses in the range of 30-40 Gy to 
the field of the entire orbit, but atrophy may occur with doses of 50-60 Gy 
Corneal ulceration has been seen after doses exceeding 60 Gy Keratitis with 
corneal ulceration can occur after 30 Gy in large fractions, but is avoided when 
conventional fractionation is used with a total dose less than 50 Gy Symblepharon 
has only been described after 80-100 Gy The sclera is resistent to radiation but 
late damage has been reported after 1000 Gy to the posterior sclera from 
Ruthenium plaques 
The lens 
A loss of normal transparency of the lens, that is cataract, can be a late effect 
after ocular irradiation The latent period between irradiation and cataract 
formation decreases as the dose increases The lens is more susceptible to radiation 
induced cataractogenesis in younger than in older patients Radiation cataract 
usually presents first as a posterior subcapsular opacification, however, a minority 
develops anterior subcapsular opacification Fractionated radiation doses of 2 Gy 
on the center of the lens, exceeding 12 Gy total dose, will cause cataract 
However, the mean latency time after lens doses of 4-10 Gy is about 6 5 years A 
single dose of 10 Gy is believed to be responsible for cataract development in 80 
% of irradiated eyes [13] 
The retina and choroid 
Radiation induced acute ultrastructural effects in the retina include changes in rod 
photoreceptors and pigment epithelial cell damage with mitochondrial swelling 
[6,8] Radiation retinopathy ι 
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and usually occurs within 3 years after treatment The frequency and extent of 
radiation retinopathy depends on the total dose, fractionation, dose rate, beam 
energy combined with radiation field arrangement, and concurrent vascular disease 
or chemotherapy Although many factors influence the development of radiation 
retinopathy, the total dose and fractionation are the most important [10] 
There are considerable difficulties in determining the exact amount of 
radiation received by the retina m patients having treatment for tumours of the 
paranasal sinuses, nasopharynx and cerebrum In the past many studies on radiation 
retinopathy were performed without CT treatment planning Retrospectively it is 
not always possible to estimate the retinal isodose curve after primary non-ocular 
treatment Differences in radiation beam direction, radiation field and fraction dose 
are all important For example, antral irradiation delivers a significant dose to the 
retina and optic nerve Sometimes the orbit may be involved in the radiation field 
because of extension of the tumor in the orbit [12] The earliest identifiable 
changes in the retinal microvasculature are focal capillary closure and irregular 
dilatation of the neighbouring microvasculature [3,6] Progressive occlusion of 
small retinal vessels with secundary ischemia and edema may occur Radiation 
retinopathy resembles diabetic and hypertensive retinopathy and is characterized 
by microaneurysms of the capillaries, cotton-wool spots, intraretinal hemorrhages 
and leakeage of retinal vessels with exudates [3,6,10,11] 
Treatment of radiation retinopathy with laser photocoagulation is indicated 
in case of peripheral retinal ischaemia and neovasculansation, but is contra-
ïndicated when severe macular ischaemia is present The addition of chemotherapy 
and the existence of diabetes mellitus may potentiate radiation retinopathy 
Mernam et al concluded that a cumulative dose of about 56 Gy, using daily 
fractions of 2 Gy, is related to a 5 % probability of late damage [20] Nakissa et 
al reported that all patients treated with doses over 45 Gy to the posterior pole had 
recognisable retinal changes, but decreased visual acuity occurred only in patients 
receiving over 65 Gy total dose [24] In most cases radiation retinopathy occurs 
0 5 to 3 years after therapy [1] A study by Midena et al stressed the importance 
of radiation damage to the anterior choroidal circulation resulting in occlusive 
changes in the choriocapillans [12] The term radiation chorioretinopathy is 
proposed instead of radiation retinopathy, because it better reflects the morphologic 
and clinical aspects of radiation damage to the chonoretina [12] 
In conclusion, severe radiation retinopathy is not observed below a total 
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dose of 50 Gy with recommended daily fractions that do not exceed 2 Gy in 
patients without vascular disease [3,6,10,11,12] 
The optic nerve 
A late radiation-induced effect is anterior optic neuropathy, presenting with a 
painless, sudden visual loss with progression over several months After a period 
of weeks to months the hemorrhagic disc swelling subsides, followed by optic disc 
palor Optic neuropathy can be expected, for example in patients treated with a 
total dose of 45-50 Gy for pituitary adenoma, with a fraction dose of more than 2 5 
Gy [13] Several authors state that radiation optic neuropathy is a consequence of 
radiation retinopathy and occurs secondary to vascular injury [6] 
The orbit 
Late effects, e g bony hypoplasia with atrophic soft tissue changes, of radiation 
on the bony orbit and secondary neoplasms are primarily seen when radiotherapy 
is applied to the growing facial bones of children, as in the treatment of 
retinoblastoma and rhabdomyosarcoma [13] Surgical reconstruction of socket 
contractures includes eyelid surgery and the use of intraorbital implants 
Side-effect 
conjunctivitis 
eyelid erythema 
dry-eye syndrome 
cataract 
radiation retinopathy 
optic neuropathy 
Minimum total dose 
(Gy) 
50 Gy 
30 - 40 Gy 
50 - 60 Gy 
4 - 10 Gy 
50 Gy 
45 - 50 Gy 
Acute or Late 
acute, within 4 weeks 
acute, within 4 weeks 
late, after > 1 year 
late, after 6 5 years 
late, after 0 5 - 3 years 
late, after > 1 year 
Figure 4. Acute and late side-effects of ocular irradiation 
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3.5 RADIOTHERAPY FOR SUBFOVEAL CHOROIDAL 
NEOVASCULARISATION (CNV) 
Introduction 
The discovery of X-rays by Roentgen in 1895 and radium by Curie in 1898 was 
the start of the introduction of new therapeutic modalities m various diseases After 
20 years of research, Rohrschneider was able to list the ocular structures in order 
of decreasing radiosensitivity lens, conjunctiva, cornea, uvea, retina, optic nerve 
[21] One of the first reports on radiotherapy for vascular ocular diseases was 
published by Guyton and Reese in 1948 [22] Their paper "Use of roentgen therapy 
for retinal diseases characterized by new-formed blood vessels" contains 
information on 14 patients with vasoproliferative retinal disease They concluded 
that in 6 eyes after a total dose of 100 Gy even the largest new vessels completely 
disappeared after 18 months of follow-up In a study treating 21 patients with 
Eales' disease, a retinal vascular disease with leakage, the value of irradiation was 
doubtful resulting in discontinuation of therapy [23] 
Unfavorable results of roentgen treatment of the posterior ocular segment in 
proliferative diabetic retinopathy were published by Larsen, treating patients with 
diabetic retinopathy with a total dose of 27 Gy with a daily fraction dose of 1-2 
Gy [24] Hayreh, in 1970, stressed the importance of fluorescein angiography in 
detecting the early microvascular changes in the retinal and choroidal vasculature 
after ocular irradiation [25] Already in 1930 Takahashi concluded, using 
histological methods, that newly developing capillaries in wound healing were very 
radiosensitive [26] 
In modern ophthalmology, radiotherapy is used to treat a variety of 
diseases [27] Benign ocular conditions like juvenile xanthogranuloma of the iris 
and diffuse choroidal haemangiomas respond well to lens-sparing radiotherapy 
[28,29] Ruthenium-plaque therapy have become standard therapy for small to 
medium sized melanoma External beam radiotherapy or teletherapy for choroidal 
involvement of leukaemia and for metastasis from solid cancer, breast cancer in 
particular, is another example of the use of X-ray therapy for ocular diseases 
Graves' ophthalmopathy and retinoblastoma are ocular-related problems that can 
also be managed by use of modern radiotherapy techniques [30] 
Recently radiotherapy has been introduced in cardiology to solve the 
problem of reststenosis after balloon angioplasty Clinical endovascular irradiation 
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via a radioactive stent with doses of 12-20 Gy appear to be efficacious in the 
prevention of this [31] The mechanism of inhibition of neointimal formation is 
related to direct radiation effects on proliferating smooth muscle cells 
Subfoveal Choroidal Neovascularisation (CNV) 
The main objective using radiation for subfoveal CNV is to induce regression and 
promote inactivation of the subretinal neovasculature with subsequent reabsorption 
of fluid and blood and reduction of the subretinal fibrosis, without harming the 
neuroretina and retinal pigment epithelium (RPE) 
Retinal vascular cells undergoing mitosis would be expected to be 
vulnerable when irradiated, and environmental factors, particulary the high oxygen 
tension on the arterial side of the circulation, contribute to the radiosensitivity of 
vascular endothelium Normal human capillaries are radiosensitive, expecting 
choroidal neovascular membranes to behave the same It remains difficult to 
predict the behavior of choroidal new vessels because the intrinsic radiosensitivity 
of these vessels is unknown The main objective using radiation is to induce 
regression of the CNV, reducing the leakage with subsequent reabsorption of 
subretinal fluid leading to small subretinal fibrosis It is hypothesized that 
radiotherapy may affect angiogenesis 1 directly by damaging neovascular 
endothelial cells and cytokme-producing macrophages resulting m mitotic death of 
these cells, 2 indirectly through effects on regulatory genes within cells which 
produce endothehal-growth regulating cytokines and, 3 by decreasing the 
inflammatory response with subsequent reduction of large scar formation [41,48] 
The potential of radiation treatment to result in regression of subretinal new 
vessels, without destruction of the overlying retina has led to clinical studies 
concerning patients with exudative AMD In 1968, Feiten published a dissertation 
"Ueber die Behandlung der feuchten Maculadegeneration durch fractionierte 
Roentgenbestrahlung des hinteren Augenpols ' [32] A total radiation dose of 1 8 
Gy in fractions of 0 3 Gy was applied to 295 eyes using 200 Kv with a field 
diameter of 3 cm After a follow-up of 6 months to 8 years (mean 3 years), it was 
concluded that 70 % of eyes showed no visual deterioration because of the 
therapeutic effect of radiation on the inflammation involved in the disciform 
response These investigations were performed without the use of angiograms with 
fluorescein injections 
74 
Radiotherapy 
Since 1955 low-dose radiation therapy has been used by Bangerter et al in 
Switzerland treating patients with neovascular AMD and various other kinds of 
ocular diseases [33] Radiation treatment is installed with "schwache-, mittelstarke-
und grenzdosierungen", dependend on the diagnosis Ocular disorders including 
retinitis centralis serosa, drusen maculopathy, high myopia and exudative macular 
degeneration have been treated with an increasing total dose of 7 5 Gy (schwach) 
in 1 fraction, 20 Gy (mittel) in 17 fractions and up to more than 20 Gy 
(grenzdosierung) in fractions of 2-3 Gy using 250 Kv and a field of 6 25 square 
cm It is stated that irradiation results in less inflammation, less vascular 
permeability and regression of neovasculansation Although interesting 
observations were described, there is no published report of this group concerning 
the efficacy of radiation treatment in any of the treated ocular diseases 
The results of the studies concerning radiation treatment in patients with 
age-related subfoveal neovascular disease performed in the University Hospital 
Nijmegen will be described in the next chapters [34,35,36,37] During recent years 
the results of many pilot studies concerning irradiation of age-related subfoveal 
CNV have been published [38-49] The experiences from these studies are positive, 
but in general the patient population studied was small the follow-up period short 
and no control group was observed 
The Belfast study group reported their results concerning irradiation of age-
related subfoveal CNV through a single lateral port, with 10-15 Gy in 5-7 fractions 
using 6 MV photons [38,39] They included patients over 60 years of age, with 
subfoveal CNV membranes for less than 3 months duration On grounds of 
experimental evidence, radiation levels in excess of 9 Gy were expected to 
influence actively replicating vascular endothelial cells After 12 months of follow 
up 63 % of the patients (n=19) maintained a stable visual acuity (VA) with a 
regression of the CNV on fluorescein angiography (FA) They concluded that 
radiotherapy had an inhibitory effect on subretinal neovasculansation reflected in 
atrophy of neovascular capillaries and decreased fluorescein dye leakage on the 
angiogram at 12 months follow-up [38] No side-effects were observed The vaso-
occlusive response became obvious as a shrinkage of new vessels at 6 months post-
irradiation, but atrophy of the CNV occurred secondary to vascular endothelial cell 
death, local thrombosis, and capillary closure [38] The authors postulated that the 
radiosensitive macrophages deprived the new vessels of vital cytokines necessary 
for growth and maintarnance In treated patients after a longer period of follow-up, 
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a reduction in scar size (SS) was reported after a mean follow-up of 28 months 
[39] Scars in radiation treated eyes occupied an area that was approximately one 
third of that in untreated fellow eyes (3 8 versus 11 7 square mm) Furthermore 
distance VA in radiation treated eyes was significantly better than that of untreated 
fellow eyes [39] After 24 months of follow-up treated eyes lost on average 12 % 
of baseline VA, whereas eyes belonging to the untreated control group lost 75 % 
of baseline VA [46] There was no evidence of radiation induced retinopathy or 
optic neuropathy in any patient 2 years post-treatment 
Finger et al described their experience with teletherapy (6 MV, total dose 
12-15 Gy) and palladium 103 ophthalmic plaque brachytherapy (apex dose 12-15 
Gy) for subretinal new vessels [41,48] They compared the intralesional, 
intraocular, and intracranial radiation dose distribution of each treatment modality 
Both treatments were associated with decreased hemorrhages, exudates, and 
leakage of neovascular membranes after a mean follow-up of 7 months After 
external beam radiotherapy transient epiphora and ocular irritation was noted in 
13 % of patients Although the results after a short period of follow-up are 
promising, well designed clinical trials remain necessary to evaluate whether 
radiation therapy is really an effective treatment for age-related subretinal 
neovasculansation and if there will be late treatment-associated morbidities 
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ABSTRACT 
Background: The natural course of the visual acuity (VA) of age-related subfoveal 
choroidal neovasculansation (CNV) membranes is poor Laser photocoagulation 
of subfoveal CNV is recommended if the patient is willing to accept a large 
decrease in VA immediately after treatment A large proportion of patients with 
subfoveal CNV do not meet the Macular Photocoagulation Study (MPS) Group 
guidelines for laser photocoagulation The fact that so few patients meet these 
criteria makes further research into new treatment techniques warranted Ionising 
radiation may prevent the proliferation of endothelial cells of newly formed 
subretinal capillaries and may induce obliteration of the aberrant new vessels 
Methods: In this study, the effect of radiation therapy on subfoveal CNV 
membranes was evaluated Four groups of ten patients were treated with external 
beam radiotherapy (16 MV photons) on an area of 1 cm2 (macular region) using 
a lens sparing technique and total dose of 8-24 Gy The first group received 8 Gy 
in one fraction The second, third and fourth groups received 12 Gy in 2 fractions, 
18 Gy in three fractions and 24 Gy in four fractions, respectively The studied 
parameters included best-corrected VA and membrane size and leakage on the 
fluorescein angiogram (FA) We included 17 occult and 23 classic CNV 
membranes as defined by the MPS, with a duration of less than 5 weeks at 
presentation Complete ophthalmic examination including fluorescein angiography 
(FA) was performed before and 3, 12 and 18 months after radiation treatment We 
analysed the angiogram using a standard over-projection sheet The results 
concerning the VA and FA were compared with the extensively published natural 
course data 
Results: The first group received 8 Gy in a single fraction In this group only four 
of ten patients had a stable visual acuity and stable FA appearance after 21 months 
of follow-up The VA and FA remained stable after 13 6 months of follow-up in 
seven of ten patients in group 2 (12 Gy) The third group (18 Gy) contained six 
patients with stable VA, although two of them, had CNV deterioration on the FA 
(111 months of follow-up) In the last group (24 Gy), with a short follow up of 
5 6 months, eight patients had a stable VA and FA appearance We did not note 
any regression of the CNV on the angiogram The VA in groups 2,3 and 4 
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decreased to 0 1 or worse in only three cases, three cases and one case respectively 
after at least 6 months of follow-up 
Conclusions: Comparison of these findings with the natural course data of 
subfoveal age-related CNV suggests a beneficial effect of radiation therapy with 
a total dose of 12 Gy or more on the progression of CNV To date no negative 
side effects have been observed 
Introduction 
Age-related macular degeneration (AMD) is a leading cause of blindness in people 
over 50 years of age in Europe and the USA The prevalence of AMD increases 
with age, from 11 % of persons between 65 and 74 years to 27,9 % in those older 
than 75 years [4] AMD represents an age related change within the retinal pigment 
epithelium, photoreceptors and Bruch's membrane The decrease in phagocytosis 
of photoreceptor membranes leads to deposition of lipofuscin material (drusen) 
within Bruch's membrane [4] Secondary atrophy of pigment epithelial cells , 
overlying photoreceptor membranes and chonocapillans results in the non-
exudative stage (dry form) of AMD The exudative stage (wet form) develops 
when new choroidal vessels penetrate Bruch's membrane, resulting in choroidal 
neovasculansation (CNV) and serous pigment epithelial detachment (PED) [4] 
Drusen which are hyperfluorescent (hydrophilic) on a fluorescein angiogram 
(FA) appear to predispose to the development of CNV The chemical composition 
of Bruch's membrane, the change in the pigment epithelium and the presence of 
macrophages which stimulate neovasculansation may all be relevant in the 
development of CNV [3] The exudative form of AMD has several clinical and 
angiographical manifestations 
The classic CNV is a choroidal capillary proliferation through a break in 
Bruch's membrane characterised on the FA by a well-demarcated area of early 
hyperfluorescence and progressive leakage in the late stages Occult CNV is a 
subretinal pigment epithelial lesion that is presumed to be a CNV because of 
associated exudative or hemoorhagic manifestations, the effect of overlying pigment 
epithelium ot the vascular growth pattern [16,21] Although fibrovascular pigment 
83 
Chapter 4 
epithelial detachments and late subretinal leakage of undetermined source are the 
common types of occult CNV according to the Macular Photocoagulation Study 
(MPS) Group [9,21] The natural course of the VA of classic CNV membranes is 
poor When the CNV is initially present within the foveal avascular zone the VA 
will be 20/200 or worse in approximately 70 % of the affected eyes within 18 
months [4] 
Laser photocoagulation of subfoveal CNV is recommended if the patient is 
willing to accept a large decrease in VA immediately after treatment On average, 
after 24 months, VA of laser treated eyes decreased three lines from baseline and 
visual acuity of untreated eyes decreased four lines [15] Although there is some 
beneficial effect of laser photocoagulation on subfoveal CNV membranes, there is 
still a considerable decrease in VA The challenge to reduce visual loss due to 
CNV has brought us to a concept in which we try to stop the growth of the 
neovascular membrane by the use of radiation therapy Ultrastructural examination 
of CNV has revealed that the cone was composed of a fibrovascular membrane 
characterised by endothehum-lined vascular channels with retinal pigment 
epithelium The rim of CNV was composed of fibrin, photoreceptor outer segments 
and macrophages [14] A CNV has been noted to grow at an average of 10 μΐη per 
day [13] 
The treatment of CNV with ionising radiation is based on two hypothesis, 
ionising radiation may prevent the proliferation of endothelial cells necessary for 
neovasculansation and may induce the obliteration of aberrant vessels The effect 
of a single dose of 8 7 Gy on normal capillaries has been described by Reinhold 
[17] Within hours there is vasodilatation and swelling and variolation of the 
cytoplasm of endothelial cells A few weeks after irradiation loss of endothelial 
nuclei occurs with a reduction in the number and lenght of the capillaries and 
occlusive changes [7,17] The clinical effectiveness of ionising radiation (doses 
between 12 5 Gy and 20 Gy) on diffuse choroidal hemangiomas associated with 
serous retinal detachments has been demonstrated by Scott et al [18] In our 
opinion occlusive changes will occur in the newly formed subretinal vessels and 
the irradiation may prevent proliferation of endothelial cells of the aberrant new 
vessels The idea of using radiation for the treatment of newly formed retinal 
vessels in the eye is not new As early as 1948, a report was published of the 
complete collaps of newly formed retinal vessels in proliferative ocular disease 
(Eales' disease) after intensive roentgen therapy [12] The aim of the present study 
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was to find a dose that would halt the proliferation of the CNV, yet entail little risk 
of cataract development. The most sensitive structure of the eye is the lens. The 
chance of cataract development is already 50 % after a dose of 5.5 Gy. The 
latency period, however, is 6.5 years after doses of 4-10 Gy [6]. We therefore 
developed a technique to avoid irradiation of the lens The oncogenic risk is about 
0.25 %. It should be kept in mind that most of them will not live long enough to 
express any radiation-induced malignancy. 
Materials and methods 
The criteria for inclusion in the study were: (1) clinically and angiographically 
proven classic or occult subfoveal CNV associated with AMD, according to the 
MPS criteria [16,21]; (2) age older than 50 years; (3) informed consent. 
Exclusion criteria were: (1) CNV associated with pathological myopia, angioid 
streaks and histoplasmosis: (2) previous photocoagulation of macular disease, (3) 
previous radiation therapy of eyes or brain. The study was performed with the 
permission of the local ethics committee for clinical experiments. 
The study population consisted of 40 patients with angiographically proven 
classic and occult subfoveal CNV membranes associated with AMD. For a 
rejection error of 5 % and a therapeutic effectiveness of 30 %, groups should 
contain 10 patients [18]. The patients were divided into the following four 
treatment groups. Group 1. ten patients received 8 Gy in one fraction. Group 2: 
ten patients received 12 Gy in two 6 Gy fractions. Group 3: ten patients received 
18 Gy in three 6 Gy fractions. Group 4: ten patients received 24 Gy in four 6 Gy 
fractions. The interval between fractions was 1 week. We used 16-MV photons on 
an area of 1 cm2 with a lens-sparing technique. 16-MV photons were chosen 
because with high-energy photons the dose administered at the surface of the eye 
is relatively low. To reduce the lens dose the beams were directed 30 degrees from 
the optical axis in the cranial/caudal direction. With this technique the lens dose 
is less than 30 % of the total dose (Figure 1). The radiation fields cross each other 
in the macular region. Outside the macular area the dose decreased to 50 % or less 
of the total dose. Patients were asked to look at a fixed point during irradiation. 
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+30° 
-30° 
Figure 1 Lens-sparing technique The radiation beams are directed 30° from the 
optical axis 
All patients had a recent history of acute decrease in VA and were submitted for 
radiation therapy within 5 weeks after the beginning of the VA drop After a 
complete ophthalmic examination including FA, best corrected visual acuity for 
distance and Amsler test, the patients were asked to participate in this pilot study 
There were no refusals All patients underwent ophthalmic examination 1 day, 4 
weeks, 3, 6, 12, 18 months after radiation therapy FA and colour photography 
were repeated 3, 12 and 18 months after radiation therapy The initial FA was 
usually performed within 10 days before the start of radiation therapy, although in 
seven patients there was a longer interval 
The early, mid-venous and late phases of the pre- and posttreatment 
angiograms were analysed using an over-projection sheet for measuring the size of 
the membrane and the leakage of fluorescein in the late phase When there was an 
increase in size of the CNV in the early phase and/or an increase in late phase 
leakage the CNV was considered to be progressive When no change between the 
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pre- and posttreatment angiograms was seen, CNV was noted as stable The 
interpretation of occult CNV development was more difficult because of the 
overlying PED and/or the obscuring blood Some of the occult CNV had a classic 
component which could be interpreted, others had leakage from an undetermined 
source which could be evaluated by comparing the pre- and post-treatment leakage 
When the overlying blood disappeared after a few months and the extension of the 
lesion using an over-projection sheet did not increase, we classified the lesion as 
stable on FA A decrease in VA was defined as a drop of two or more lines of the 
Snellen test Stable VA was defined as an increase or decrease within two lines 
from initial best-corrected VA A two-line drop of VA in our test is comparable 
to a three-line drop in the data used in the MPS study on subfoveal CNV [15] 
RESULTS 
The initial (baseline) FA showed in 23 patients a classic CNV membrane and in 
17 patients an occult membrane as defined by the MPS [15] In a recent article the 
presenting clinical findings were evaluated concerning the neovascular form of 
AMD [10] About 87 % of the presenting patients had occult CNV, with 84 % 
having subfoveal disease [10] It is difficult to include only classic CNV, because 
of the high number of cases of occult CNV 
Group 1 In the first group (8 Gy in one fraction, Table 1) the mean follow-up was 
21 months (rangel7-24 months) The average age was 77 8 years (range 74-87 
years) In six patients there was a decrease in VA to 0 1 or worse after radiation 
treatment The VA drop occurred in all patients within 3 months after treatment 
In the other four patients the VA remained stable with no deterioration of the CNV 
membrane on the FA Only one of three occult CNV membranes remained stable 
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Table 1 Radiation therapy. 8 Gy in 1 fraction (group 1) 
case 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
age/ 
gender 
74/F 
76/M 
74/M 
82/F 
74/M 
87/M 
74/M 
77/M 
77/F 
83/M 
VA inclusion 
0 25 
0 3 
0 16 
0 1 
0 2 
0 3 
0 3 
0 4 
0 3 
0 2 
VA final 
0 3 
0 1 
1/60 
0 25 
2/60 
0 3 
0 2 
0 1 
1/60 
0 08 
follow-up 
(months) 
22 
17 
18 
22 
22 
24 
22 
19 
21 
23 
FAG 
stable 
worse 
worse 
stable 
worse 
stable 
stable 
worse 
worse 
worse 
CNV 
type 
classic 
classic 
occuh 
classic 
classic 
classic 
occult 
occult 
classic 
classic 
Table 2. Radiation therapy. 12 Gy m 2 fractions of 6 Gy (group 2) 
case 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
age/ 
gender 
85/F 
79/M 
77/M 
80/M 
69/F 
69/F 
90/F 
58/F 
82/F 
84/F 
VA inclusion 
0 3 
0 3 
0 25 
0 3 
1/60 
0 16 
0 16 
0 5 
0 125 
3/60 
VA final 
2/60 
0 25 
0 3 
0 3 
1/60 
0 2 
0 08 
0 4 
2/60 
1/60 
follow-up 
(months) 
13 
11 
12 
15 
15 
14 
14 
14 
13 
15 
FAG 
worse 
stable 
stable 
stable 
stable 
stable 
worse 
worse 
worse 
stable 
CNV 
type 
classic 
classic 
classic 
occult 
classic 
classic 
occult 
occult 
occult 
classic 
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Group 2 The mean follow-up in the second group (12 Gy in two fractions, Table 
2) was 13 6 months (range 11-17 months) and the average age was 77 3 years 
(range 58-90 years) There was stable VA in seven patients, although one patient 
(no 8) had signs of deterioration on the FA Only one of four (no 4) occult 
membranes remained stable concerning the VA and the FA apperance, the other 
three had a decrease in VA to 0 1 or worse 
Group 3 The third group (18 Gy in three fractions, Table 3) with a mean follow-
up of 11 1 months (range 8-14 months) and an average age of 76,9 years (range 
68-84 years), contained only three classic membranes Four patients had a decrease 
in VA (three with a VA of 0 1 or worse) after radiation therapy and they all had 
an initial occult CNV In five patients the VA remained stable, with in three 
patients no change in FA appearance In two patients (nos 5,9) FA deterioration 
occurred Patient no 1 had an increase in VA because of the dissappearance of 
subretinal fluid associated with the CNV 
Table 3. Radiation therapy 18 Gy in 3 fractions of 6 Gy (group 3) 
case 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
age/ 
gender 
72/M 
82/M 
80/F 
84/F 
71/F 
79/F 
75/F 
76/F 
68/M 
82/F 
VA inclusion 
1/60 
0 3 
0 25 
0 2 
0 25 
0 3 
0 25 
0 3 
0 2 
0 3 
VA final 
0 2 
0 25 
1/60 
1/60 
0 25 
0 25 
0 08 
0 3 
0 25 
0 16 
follow up 
(months) 
10 
12 
8 
14 
14 
14 
10 
9 
9 
11 
FAG 
stable 
stable 
worse 
worse 
worse 
stable 
worse 
stable 
worse 
worse 
CNV 
type 
classic 
classic 
occult 
occult 
occult 
occult 
occult 
occult 
classic 
occult 
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Group 4. The mean follow-up in the fourth group (24 Gy in four fractions; Table 
4) was 5.6 months (range 4-7 months) and the average age was 74.3 years (range 
69-83 years). Only one patient had a decrease in VA according to our definition, 
but patient no. 6 had a slight decrease in VA associated with a deterioration on the 
FA. The other eight patients, including two occult CNV membranes (nos. 2,7), had 
stable VA and FA appearance. 
Table 4. Radiation therapy. 24 Gy in 4 fractions of 6 Gy (group 4) 
case 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
age/ 
gender 
70/M 
69/F 
78/F 
72/F 
81/F 
70/M 
83/M 
74/M 
75/M 
71/M 
VA inclusion 
0.3 
0.2 
0 08 
0 25 
0 2 
0 2 
0 16 
0 5 
0 16 
0.4 
VA final 
0 25 
0 2 
1/60 
0 25 
0 2 
0 1 
0 16 
0 5 
0 125 
0 3 
follow-up 
(months) 
6 
6 
7 
6 
4 
7 
4 
6 
5 
5 
FAG 
stable 
stable 
worse 
stable 
stable 
worse 
stable 
stable 
stable 
stable 
CNV 
type 
classic 
occult 
occult 
classic 
classic 
classic 
occult 
classic 
classic 
classic 
In group 1, a decrease in VA and an FA deterioration occurred in six patients. 
Only four patients had a stable VA and FA after therapy (21 months follow-up). 
In three patients of group 2 the VA and FA deteriorated, and in seven patients 
there was a stable situation (13.6 months follow-up). The third group, with seven 
initial occult CNV membranes, had six patients with stable VA after treatment but 
two of them showed FA deterioration (111 months follow-up). In group 4, stable 
post-irradiation VA and FA occurred in eight patients, but with a relatively short 
follow-up (5.6 months) Except for the two patients (nos.5,9) in group 3, all the 
patients with a stable VA had a CNV membrane that remained unchanged on FA 
appearance after radiation therapy (Figure 2). None of the patients showed CNV 
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membrane regression on FA appearance If a drop in VA or a deterioration on the 
angiogram was noticed, it occurred within 3 months after treatment (Figure 3) 
None of the patients noticed any side effect of this therapy Complications such as 
radiation keratitis or radiation retinopathy were not encountered Slight changes in 
lens opacification could not be ruled out, but we did not notice a substantial 
progression of cataract in our patients We are aware of the fact that the follow-up 
is still short and that some side-effects become apparent only after several months 
or years 
Discussion 
The prevalence of AMD in a general population over the age of 65 years is about 
25 % Although only 12 % of patients with AMD have the exudative stage, they 
constitute 88 % of those who become legally blind [8] No control group was 
included in this study because the natural course of subfoveal membranes is well 
documented [3,5,11,19] The natural course of classic CNV membranes in AMD 
has been described by Bressler et al [3] A subfoveal CNV, with an initial VA of 
0 1 or better, shows in at least 70 % of the eyes a VA of 0 1 or worse after 21 
months of follow-up Guyer et al found that 77 % of eyes with a subfoveal CNV 
had lost at least four lines of VA after 24 months follow-up [10] The natural 
course of occult CNV membranes with an initial VA of 0 25 shows a decline of 
at least three lines in 63 % of patients after 28 months of follow-up [5] The 
natural course of a PED with a CNV is even worse Some 86 % of patients with 
an initial VA better than 0 2 and a subfoveal CNV associated with a PED had a 
final VA of 0 1 or worse after 48 months follow-up [20] 
The MPS recommends laser photocoagulation for classic subfoveal CNV 
membranes if the patient is willing to accept a large decrease in VA immediately 
after treatment In the long term, treated patients had less decrease in VA from 
baseline Persistent or recurrent CNV was observed in 51 % of the laser treated 
eyes by 24 months after initial treatment [14] Penfoveal laser photocoagulation 
has also been proven to be effective m the short term preservation of VA, but this 
treatment led to a six line VA loss after 42 months in 76 % of patients [8] 
Compared with eyes in natural history studies, eyes treated with unconventional 
scatter macula photocoagulation had less visual loss from baseline but did not 
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recover VA of 0.2 or better more frequently [21]. Except for the limited benefit 
of laser photocoagulation there is no therapeutic modality for patients with CNV 
membranes. 
In 1992 we reported the preliminary results of this study [2]. Chakravarthy 
et al. recently reported a beneficial effect of teletherapy with 6-MV photons (doses 
10-15 Gy in five fractions) on subfoveal CNV [7]. VA was maintained or 
improvred in 78 % and 63 % of the patients at their 6- and 12 months follow-up 
examination, respectively. Significant CNV regression was recorded in 68 % and 
77 % of treated patients at 6 and 12 months after irradiation. No differences were 
seen between patients who received 10 Gy and those who received 15 Gy. The 
vaso-occlusive response became obvious at 6 months after irradiation [7]. The 
present work showed that a single fraction of 8 Gy had no beneficial effect Only 
four of ten patients had stable VA and FA appearance after 21 months, which is 
comparable with the natural history of subfoveal CNV membranes. In the second 
group (12 Gy in two fractions) and the third group (18 Gy in three fractions), VA 
remained stable for at least 12 months in seven and six cases, respectively. These 
results are comparable with the outcome of the study by Chakravarthy et al. [7] 
In contrast with their angiographically proven CNV regression we could note only 
inhibition of the expansion of the CNV membranes in the majority of our patients 
with stable VA. Two patients (nos. 5,9) of the third group had FA deterioration 
but stable VA. These patients had a period of 4 weeks between the baseline FA 
and the first radiation treatment Compared with the other groups, the fourth group 
(24 Gy in four fractions) had only a short follow-up (5.6 months), but it is 
promising that eight of ten patients had a stable VA and FA appearance 
The differences in angiographic outcome between the two studies may be 
due to differences in treatment volume. In the present study only 1 square cm of 
the choroid was irradiated, while Chakravarthy et al. treated more than 50 % of 
the choroid. Other reasons for differences in post-treatment changes in FA 
appearance are a delay of more than 10 days between the initial angiogram and 
initiation of treatment (group 2, nos.7,8,9; group 3, nos. 3,5,9; group 4, no.6) and 
a larger percentage of occult membranes in the present study. The presence of an 
occult CNV membrane (17/40 patients) sometimes made it difficult to compare the 
initial and final FA. It should be noted that in contrast to the study by 
Chakravarthy et al., in which only four of the 19 patients had an initial VA of 6/24 
or more, in our study 22 of the 40 patients presented with initial VA of 25/100 or 
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more We also excluded patients with previous laser treatment, whereas the other 
study contained five patients with previous laser treatment in the macular region 
To date we have seen no side effects of radiation therapy According to the 
literature the lens is the most sensitive part of the eye for radiation damage 
[1,6,17] With the lens-sparing technique we used, the expected lens dose is less 
than 30 % of the total dose In group 3 (18 Gy) and group 4 (24 Gy), with lens 
doses of 6 Gy and 8 Gy, respectively, there remains a possibility of cataract 
development 
In conclusion, stable VA was observed in six to eight of the ten patients in each 
of the groups 2,3 and 4 (12 Gy, 18 Gy and 24 Gy), associated with a stable CNV 
membrane on FA in all except two cases The MPS data show that the VA of eyes 
with untreated subfoveal CNV with an initial VA of 0 1 or better will decrease to 
0 1 or worse in 44 % of eyes within 3 months of follow-up [15] The VA in our 
groups 2, 3 and 4 decreased to 0 1 or worse in three,three and one patient, 
respectively, after at least 6 months of follow-up Although the follow-up is still 
short (especially in group 4), patients treated with total doses of 12 Gy or more 
seem to do better than one might expect from the natural history of this disease 
To date no negative side effects have been observed Longer observations will 
show whether the proposed treatment is indeed safe The positive results of the 
present study, however, warrant further investigation to determine the role of 
radiation therapy in the treatment of CNV membranes 
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Figure 2. Patient 2 (12 Gy group). Visual acuity in left eye 0.3 before treatment 
and 0.25 after treatment (follow-up 12 months). 2a, Early phase before treatment. 
2b, Late phase before treatment. 2c, Early phase 12 months after treatment. 2d, 
Late phase 12 months after treatment. 
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Figure 3. Patient 9 (18 Gy group). Visual acuity in left eye 0.2 before treatment 
and 0.25 after treatment (follow-up 9 months). 3a, Early phase before treatment. 
3b, Late phase before treatment. 3c, Early phase 3 months after treatment. 
3d, Late phase 3 months after treatment. 
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ABSTRACT 
In this pilot study the effect of radiation therapy on subfoveal CNV membranes 
associated with AMD was evaluated Four groups of 10 patients were treated with 
external beam radiotherapy (16 MV photons) on an area of 1 cm2 (macular region) 
using a lens-sparing technique and a total dose of 8 to 24 Gy The first group 
received 8 Gy in a single fraction In this group only 30 % had a stable visual 
acuity and a stable FA after 18 months of follow-up In 50 % of patients in group 
2 (12 Gy) and 40 % of patients in group 3 (18 Gy) the visual acuity (VA) and FA 
appearance remained stable after 18 months of follow-up In the last group (24 Gy) 
80 % of patients had a stable VA and FA appearance after 12 months follow-up 
Comparison of these findings with the natural history data of subfoveal age-related 
CNV, suggests a beneficial effect of radiation therapy with a total dose of 12 Gy 
or more on the progression of CNV membranes 
Introduction 
AMD is a leading cause of blindness in people over 50 years in Europe and the 
USA The prevalence of AMD increases with age to 25 % in those older than 65 
years [1] Although only 12 % of patients with AMD have the exudative stage with 
the development of a CNV, they constitute 88 % of those who become legally 
blind [2] The indications for laser treatment of subfoveal CNV have been well 
defined by the Macular Photocoagulation Study (MPS) group But a recent article 
by Yannuzzi et al suggests that a large proportion (87%) of patients with 
neovascular AMD do not meet the MPS guidelines for laser treatment Because so 
few patients meet these criteria, further research into new techniques for treatment 
of this disorder is warranted [3] 
The natural course of th VA of subfoveal CNV membranes is poor When 
a CNV is initially present within the foveal avascular zone the VA will be 20/200 
or worse in approximately 70 % of the affected eyes within 18 months [1] The 
treatment of CNV with ionising radiation is based on the hypothesis that ionising 
radiation may prevent the proliferation of endothelial cells necessary for 
neovasculansation and may induce the obliteration of aberrant vessels [4] The 
most sensitive structure of the eye concerning irradiation is the lens The latency 
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time between the radiation treatment and the development of cataract after a total 
dose of 4 to 10 Gy will be 6 5 years on average [5] 
Materials and methods 
We included 40 patients with an angiographically proven classic or occult subfoveal 
CNV associated with AMD and a VA of 0 1 or better at presentation This study 
was performed with permission of the institutional ethical committee for clinical 
experiments The first group of 10 patients (mean age 77 years) received 8 Gy in 
1 fraction The second group (mean age 77 years) received 12 Gy m 2 fractions 
The third group (mean age 76 years) and the fourth group (mean age 74 years) 
received 18 Gy in 3 fractions and 24 Gy in 4 fractions respectively The baseline 
FA showed in 23 patients a classic CNV membrane and in 17 patients an occult 
CNV membrane as defined by the MPS [6,7] Most patients had a recent history 
of acute decrease in VA based on subfoveal CNV, and were treated within 5 weeks 
after the beginning of the drop in VA All patients underwent a complete 
ophthalmic examination including fluorescein angiography before treatment and 3, 
12 and 18 months post-treatment 
The early, mid venous and late phase of the pre- and post-treatment 
angiograms were analysed using an over-projection sheet for measuring the size of 
the membrane and the leakage of fluorescein in the late phase When there was an 
increase in size of the CNV in the early phase and/or an increase in late phase 
leakage the CNV membrane was considered to be progressive When no change 
between the pre and post-treatment angiograms was seen, the CNV was noted as 
stable A decrease in VA was defined as a drop of 2 or more lines at the Snellen 
test A stable VA was defined as an increase or decrease within 2 lines from initial 
best corrected VA We used 16 MV photons on an area of 1 cm2 with a lens 
sparing technnique 
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Results 
In the first group (n= 10,8 Gy), only 3 patients had a stable VA and FA after 18 
months of follow-up The drop m VA occurred in 6 patients within 6 months after 
treatment The second group (n= 10, 12 Gy) contained 7 patients with a stable VA 
and FA after 12 months of follow-up, but in two patients a deterioration occurred 
12 months after treatment The third group (n = 10, 18 Gy), with 7 occult CNV 
membranes, showed in 4 patients a stable VA and FA after 18 months of follow-
up After 12 months of follow-up there were 6 stable patients Only 2 patients in 
the fourth group (n= 10, 24 Gy) had a decrease in VA and a FA deterioration after 
12 months of follow-up The other 8 patients were all stable after one year The 
results are summarised in Table 1 
Table 1. Number of patients with a stable visual acuity (VA) and a stable 
fluorescein angiogram (FA) after radiation treatment 
Group (n=10) 
Group 1 
8 Gy 
Group 2 
12 Gy 
Group 3 
18 GY 
Group 4 
24 Gy 
No classic 
No occult 
total 
7 classic 
3 occult 
10 total 
6 classic 
4 occult 
10 total 
3 classic 
7 occult 
10 total 
7 classic 
3 occult 
10 total 
follow-up 
6 months 
3 
1 
4 
6 
1 
7 
3 
3 
6 
6 
2 
8 
follow-up 
12 months 
2 
1 
3 
6 
1 
7 
3 
3 
6 
6 
2 
8 
follow-up 
18 months 
2 
1 
3 
4 
1 
5 
2 
2 
4 
9 
9 
9 
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After 12 months of follow-up 60-80 % of patients in group 2, 3 and 4 show a 
stable VA and FA appearance, but after this period 2 eyes in group 2 and 3 
deteriorated. None of these patients noticed any side effect of this therapy. 
Complications such as radiation keratitis were not encountered. Slight changes in 
lensopacification could not be ruled out, but we did not notice a substancial 
progression of cataract in our patients. 
Figure 1. Case study. Male patient, left eye, visual acuity 0.3, 12 Gy group. 
la, Early phase before treatment, lb, Late phase before treatment. 1c, Early phase 
one year after treatment. Id, Late phase one year after treatment. 
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Discussion 
In this study a control group was not included because there is well documented 
information about the natural course of subfoveal CNV membranes [1,8,9,10] The 
natural course of classic CNV membranes has been described by Bressler et al A 
subfoveal CNV, with an initial VA of 0 1 or better, shows in at least 70 % of the 
eyes a VA of 0 1 or worse after 18 months of follow-up [1,9] The natural course 
of occult CNV is even worse [11] The MPS Group compared the VA after 
laserphotocoagulation of subfoveal CNV with the natural course findings of 
subfoveal CNV [6,7] The VA of eyes with untreated subfoveal CNV with an 
initial VA of 0 1 or better, will decrease to 0 1 or worse in 44 % of eyes after 3 
months follow-up and m 80 5 % of eyes after 24 months of follow-up [6] 
Laserphotocoagulation of subfoveal CNV has some beneficial effect, but the patient 
must be prepared for a large decrease in visual acuity immediately after treatment 
[6] After 18 months follow-up 7 patients in the 8 Gy group had a VA of 0 1 or 
worse, which is comparable to the natural course data In the 12 Gy and 18 Gy 
group, 3 and 4 patients respectively had a VA of 0 1 or worse after 12 months, but 
m both groups 2 other patients had a drop in VA within 18 months of follow up 
Although the follow up in the 24 Gy group is not exceeding 12 months, 8 out of 
10 patients remained stable, and only 2 patients had a decrease in VA to 0 1 or 
worse When compared to the natural history data (44 % of eyes develop a VA of 
0 1 or worse within 3 months), the patients treated with 12,18 and 24 Gy show less 
loss of VA (20-40 % a VA of 0 1 or wores within 12 months) There is a 
possibility that the radiation treatment has decreased or stopped the growth speed 
of the neovascular membrane 
A Belfast study group reported a beneficial effect of teletherapy, with 6 MV 
photons and total doses of 10-15 Gy in 5 fractions on subfoveal CNV After 12 
months follow-up the VA was maintained or improved in 63 % of patients and they 
noticed a CNV regression in 77 % of patients on the angiogram [12] Their results 
concerning the VA are comparable with the results of the 12, 18 and 24 Gy group 
after 12 months of follow-up In contrast to their angiographically proven CNV 
regression we could only note an inhibition of the expansion of the CNV 
membrane after irrsdiation The differences in angiographical outcome may be due 
to differences in treatment volume In the present study only 1 cm2 of the choroid 
received a total dose, while the whole choroid of the eye in the Belfast study was 
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treated with the total dose The presence of occult CNV (43 % of eyes) made it 
sometimes difficult to compare the initial and final FA appearance in our pilot 
study 
In conclusion, after 12 months of follow up patients treated with 12 and 18 
Gy total dose, show more patients with a VA of 0 1 or better than you might have 
expected from the natural course The 24 Gy group, with 8 stable patients after 12 
months, shows promising results Although the follow up is still short, the patients 
treated with low doses of irradiation seem to do better than one might expect from 
the natural history data Until now there are no negative side effects, but longer 
observation is needed for a definite answer The results of the Belfast study and 
this pilot study warrant further investigation to determine the role of radiation 
treatment of CNV membranes, knowing that cumulative doses of radiation up to 
25 Gy causes no observable damage to the neuroretina and optic nerve [4] The 
final answer has to come from a randomized study including a control group of 
patients 
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ABSTRACT 
Purpose and methods: In a pilot study to determine the effectiveness of ionizing 
radiation on the deterioration of subfoveal choroidal neovasculansation (CNV), 
the affected eyes of 10 patients were treated with a total dose of 24 Gy (6 Gy 
fractions) A special lens-sparing technique was used to avoid cataract 
development During 30 months of follow-up the visual acuity (VA) and scar 
size (SS) of the treated eyes of all 10 patients were evaluated The ten fellow 
eyes included four eyes with untreated age related disciform scarring already 
present at inclusion 
Results: After 30 months of follow-up 5 treated eyes showed a stable VA and 
fluorescein angiogram (FA) appearance The other 5 eyes had progressive 
disease We were able to compare 4 eyes with progressive disease after radiation 
treatment, with 4 fellow eyes with untreated age related disciform lesions already 
present at inclusion The 4 eyes treated with radiation therapy had better VA and 
smaller SS, 30 months after inclusion, compared with the untreated fellow eyes 
with a stable disciform scar 
Conclusions: The results suggest that radiation with 24 Gy either stabilizes or 
delays the deleterious effects of CNV on the visual acuity and scar size Until 
now no late side effects have been observed 
Introduction 
The exudative form of age-related macular degeneration (AMD), with the 
development of choroidal neovasculansation (CNV), is a leading cause of 
blindness in western countries The effect of laser photocoagulation for selected 
cases of subfoveal CNV is well known from the macular photocoagulation study 
(MPS) investigations [1,2,3,4] The patient must accept an immediate and perma-
nent decrease of VA after laser photocoagulation, but will have better VA using 
low-vision aids [1,2,3] Only in case of a small CNV with a moderate or poor 
108 
Pilot 
VA foveal ablation is recommended [4]. Other modalities of 
laserphotocoagulation including foveal sparing techniques are being proposed as 
alternative treatments but their definitive value has not been proved [5] Only a 
few patients with recent subfoveal CNV are suitable for laser therapy, because a 
large proportion (87 %) of patients have an occult or poorly-defined CNV at 
presentation [6]. Alternative forms of therapy for CNV are proposed, like 
submacular surgery, Interferon therapy, ICG-guided laser therapy and 
Thalidomide therapy but none of these new therapies seems to be valuable [7]. 
Patients with unilateral age-related exudative maculopathy developed neovascular 
membranes in the fellow eye in 31 % of cases after 4 years of follow-up, and in 
general patients with exudative disease in one eye develop CNV in the fellow eye 
at a rate of about 5-10 % per year [8]. 
The hypothesis that ionizing radiation may prevent endothelial cell 
proliferation and/or induce aberrant vessel obliteration and influences 
macrophages depended growth factors and/or regulatory genes, in case of CNV, 
is under investigation [7]. After the first report concerning the effect of radiation 
therapy on subfoveal CNV in 1992, several other reports were published 
[9,10,11,12,13,14]. We are now able to present the results after 30 months of 
follow-up concerning ten patients treated with radiation therapy with a total dose 
of 24 Gy (6 Gy fractions). We decided to do a longer follow-up in this group of 
patients because initially they showed the best results after 12 months post-
irradiation in our pilot study [11,13]. 
Materials and methods 
This study was performed with permission of the institutional ethical committee 
for clinical experiments. The early results of this group of patients were 
previously published [11,13]. Ten patients with subfoveal CNV and recent 
decrease of VA were treated with a total dose of 24 Gy in 4 fractions of 6 Gy in 
the macular area. The time between two consecutive fractions was 1 week and 
the overall treatment time was 3 weeks. The dose was delivered by two 1 cm2 16 
MV photon beams. The two photon beams diverge 30 degree from the eye axis 
and cross the eye axis in the macular area. By this technique the lens will receive 
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less than 30 % of the total dose All patients underwent a complete ophthalmic 
examination of both eyes, including FA, before treatment and 3, 12, 18 and 30 
months post treatment The early, mid and late venous phase of the pre- and 
post-treatment angiograms were analysed using an over-projection sheet for 
measuring the size of the membrane (disc areas = DA) and the leakage of 
fluorescein in the late phase When there was an increase in size of the CNV in 
the early phase and/or an increase m late phase leakage the CNV membrane was 
considered to be progressive When no change between the pre- and post-
treatment angiograms was seen, the CNV was considered as stable Any CNV 
with a classic component but partial occult (including subretinal blood and/or 
fluid or late undetermined leakage) was classified as occult type of CNV A 
decrease in VA was defined as a drop of 2 or more lines at the Snellen test A 
stable VA was defined as an increase or decrease within 2 lines from initial best 
corrected VA After 30 months of follow-up the VA and FA of the treated eyes 
and fellow eyes of all 10 patients were documented 
Results 
The patients treated with a total dose of 24 Gy (6 Gy fractions) showed the 
following characteristics (Table 1 and Table 2) 
Patient 1 Male, 72 years 
He presented with a classic type of CNV in the right eye and an initial VA of 
0 3 (Figure 1, before treatment, left) After 30 months of follow-up the VA was 
0 2 and the central SS was 1 DD (Figure 1, after treatment, right) His fellow 
left eye showed drusen and a VA of 1 0 
Patient 2 Female, 71 years 
This patient initially had a VA of 0 2 and an occult type of CNV After 30 
months the VA dropped one line to 0 1 and the FA appearance of the CNV 
remained stable with a scar size of 2 DD Her fellow eye with a scar of 2 DD 
had a VA of 0 4 
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Patient 3 Female, 80 years 
This patient showed a drop in VA from 0 08 to 1/60 within 3 months after 
radiation therapy for occult CNV After 30 months of follow up her VA in the 
study eye is 1/60 with a SS of 6 DD Her fellow eye already had disciform 
scarring for more than one year without laser treatment at presentation, with a 
SS of 12 DD After 30 months of follow up the SS in the fellow eye stabilized 
and the VA remained 2/300 
Patient 4 Female, 74 years 
This patient presented with a classic CNV (OD) and an initial VA of 0 25 
(Figure 2, OD before treatment, left) A drop in VA occurred after 18 months 
post-radiation treatment and she ended up with a VA of 0 1 and a SS of 2 DD 
after 30 months (Figure 2, OD after treatment, right) The fellow left eye 
showed untreated disciform scarring present for more than one year at 
presentation and with a stable SS of 6 DD and a VA of 2/60 after 30 months of 
follow up (Figure 3) 
Patient 5 Female, 83 years 
The left eye with a classic CNV and an initial VA of 0 2 showed a stable 
angiogram with a SS of 2 DD after 30 months The VA decreased to 0 125 after 
30 months post-treatment The fellow eye has a VA of 0 8 and drusen in the 
macular area 
Patient 6 Male, 72 years 
This patient presented with a classic CNV with an initial VA of 0 2 A decrease 
in VA to 0 1 after 6 months and to 1/60 after 12 months post-treatment 
occurred The SS of 1 DD at presentation enlarged to 4 DD at 30 months of 
follow-up The fellow right eye still has a VA of 0 8 and has some pigmentary 
changes in the macular area 
Patient 7 Male, 85 years 
Between 12 and 18 months after treatment for occult CNV, the VA declined 
from 0 16 to 2/60 and after 30 months the VA is 2/60 with a SS of 5 DD The 
fellow eye with a VA of 1/60 had disciform scarring, without previous laser 
treatment, at presentation with a SS of 6 DD 
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Patient 8: Male 76 years. 
The left eye with classic CNV and an initial VA of 0.5 showed a decrease in VA 
to 0.2 after 12 months and to 0.08 after 30 months of follow-up with an increase 
in SS from 1 DD to 3 DD. The fellow eye with a VA of 1/60 and a scar size of 
4 DD at presentation remained stable during 30 months of follow-up. This eye 
was not treated with laserphotocoagulation. 
Patient 9: Male 77 years. 
The right eye presented with a classic CNV and a VA of 0.16. At the end of the 
follow-up period the VA increased to 0.25 and the FA remained stable. The 
fellow eye with some drusen had a stable VA of 0.8. 
Patient 10: Female 73 years. 
This patient with a classic CNV had a stable VA of 0.3 during the follow-up 
period, with a SS size of 1 DD. The fellow eye with a VA of 0 8 did not show 
any change. 
Table 1. Patients (n = 5) with stable visual acuity (VA) and scar size (SS) on 
fluorescein angiography 30 months after radiation therapy with a total dose of 24 
Gy (6 Gy fractions) compared with the untreated fellow eye. 
Patient 
No 
1. 
2. 
5 
9. 
10. 
Study eye 
VA 
0.2 
0.1 
0.125 
0.25 
0.3 
Study eye 
SS 
1 DA 
2 DA 
2 DA 
2 DA 
1 DA 
Fellow eye 
VA 
1.0 
0.4 
0.8 
0 8 
0 8 
Fellow eye 
SS 
drusen 
2 DD 
drusen 
drusen 
drusen 
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Table 2 Patients (n=5) with deterioration of visual acuity (VA) and scar size 
(SS) on fluorescein angiography 30 months after radiation therapy with a total 
dose of 24 Gy (6 Gy fractions) compared with the untreated fello л> eye 
Patient 
No 
3 
4 
6 
7 
8 
Study eye 
VA 
1/60 
0 1 
1/60 
2/60 
0 08 
Study eye 
SS 
6 DA 
2 DA 
4 DA 
5 DA 
3 DA 
Fellow eye 
VA 
2/300 
3/60 
0 8 
1/60 
1/60 
Fellow eye 
SS 
12 DD 
6 DD 
drusen 
6 DD 
4 DD 
Thirty months after radiotherapy, with a total dose of 24 Gy, 5 out of 10 patients 
have a stable VA without progression of the CNV on FA (Table 1) Patient 1 5, 
9 and 10 presented with a classic CNV, while patient 2 had an occult CNV The 
VA initially was better than 0 1 and remained stable in all cases at 30 months 
after radiotherapy The other 5 patients had progressive disease with a decrease 
in VA and an increase in SS despite radiation therapy (Table 2) Patient 3, 6 and 
7 ended up with a VA of finger counting at 1 or 2 meter, while patient 4 and 6 
had a VA of 0 1 and 0 08 respectively after 30 months Four (patient 3,4,7,8) of 
the the 5 patients with progressive disease, had untreated disciform scarring in 
the fellow eye at presentation The 4 eyes treated with radiation therapy had 
better VA and smaller SS compared with the untreated fellow eyes after 30 
months of follow-up (Table 2) Until now we did not see any severe side-effects 
of this radiation therapy such as radiation retinopathy or dry eyes Slight changes 
in lensopacification, however, can not be ruled out 
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Discussion 
In exudative AMD new capillaries proliferate under the retinal pigment 
epithelium and/or between the retinal pigment epithelium and the retina after 
they have broken through Bruch's membrane They leak blood, lipoproteins and 
subretinal fluid in the active phase Over a period of months fibrous tissue 
appaers with the development of a fibrovascular disciform scar, with secundary 
destruction of the overlying photoreceptors and the remaining retinal pigment 
epithelium 
According to Bird there are no well formulated concepts concerning the 
mechanism by which neovasculansation is induced Maybe macrophages cause 
vasoprohferation by producing growth factors [15] Finger et al concluded after 
reviewing the literature that possibly radiotherapy indirectly effect genes 
resulting in growth arrest and/or apoptosis [14] The Belfast study group 
postulated that radiotherapy acts to minimise size and intensity of the disciform 
response, through arresting the proliferation of endothelial cells resulting in 
mitotic cell death and through its attenuating effects on the inflammatory 
response resulting in a reduced disciform scar [12] Their results concerning 
radiotherapy for exudative AMD are encouraging, because the VA was 
significantly better and the SS was smaller in 11 eyes treated with radiotherapy, 
compared with the untreated fellow eyes with disciform scarring after a mean 
follow-up of 28 months After reviewing the literature they concluded that 
concordance in scar size between the eyes of untreated patients was found to be 
highest when the duration of the disease was at least 12 months in the second eye 
to be affected This implies that the appearance of the fibrovascular disciform 
scar does not change substantially after 12 months from initial presentation [12] 
The natural course of the visual acuity in patients with classic or occult 
CNV is lcnown from many studies [1,2,3,4] The VA of eyes with untreated 
subfoveal CNV with an initial VA of 0 1 or better, will decrease to 0 08 or 
worse in 44 % of eyes after 3 months of follow-up and in 80 5 % of eyes after 
24 months of follow-up When compared to the natural course of the disease 
(80 5 % of eyes deteriorate to a VA of 0 08 or worse within 24 months) 
radiation the dose of 24 Gy seems to have a beneficial effect on the VA (3 of 10 
eyes had a VA of 0 08 or worse within 30 months) Although 5 eyes showed 
progresssive disease after radiation therapy, we noticed in 4 of them a better VA 
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and smaller SS after 30 months, when compared with the untreated fellow eyes 
with exudative AMD These results confirm the results of the Belfast study 
group [12] Radiation may have some negative side effects on the eye when 
doses are given beyond tolerance levels The lens is a relatively radiosensitive 
structure and opacification will develop when doses exceed 6-12 Gy In this 
study the radiation was applied in such a way that the lens was more or less 
spared Until now there are no indications that there is an increased incidence of 
cataract in the treated eyes More severe side-effects such as radiation 
retinopathy or radiation optic neuropathy are rare after doses of 46 5 Gy and 55 
Gy (2 0 Gy fractions) respectively [16] Four fractions of 6 Gy, given in 3 
weeks, is more or less biologically equivalent to 50 Gy given in 25 daily 
fractions of 2 Gy The incidence of radiation damage after 24 Gy (6 Gy 
fractions) is expected to be very low and quite safe [16,17] As expected no 
cases of radiation retinopathy are observed until now 
In conclusion, after a substantial period of follow-up (30 months), 7 out 
of 10 patients treated with a total dose of 24 Gy (6 Gy fractions) in the macular 
area, maintained a VA of 0 08 or better while, concerning the natural course 
data, 20% was expected This data, including the reduction in scar area after 
radiation treatment, suggest a beneficial effect of radiation therapy in subfoveal 
exudative age-related disease The overall conclusion during the meeting of the 
American Academy of Ophthalmology in October 1995 was that there is a strong 
theoretical basis for this therapy but that a definite answer has to come from 
long-term prospective randomized controlled trials In several centers over the 
world, including in the Netherlands, 
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Figure 1. Patient 1 with a classic type of CNV of the right eye and a VA of 0.3 
at presentation before radiation treatment (left). The VA was 0.2, 30 months after 
radiation treatment (right). Top left, red free picture at presentation. Bottom 
left, early phase at presentation. Top right, red free, 30 months after 
radiotherapy. Bottom right, early phase 30 months post-treatment. 
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Figure 1. Patient 1 with a classic CNV of the right eye and a VA of 0.3 at 
presentation and a VA of 0.2, 30 months after radiation treatment. Left, late 
phase at presentation. Right, late phase 30 months after radiation therapy. The 
late phase picture (right) shows a central SS of 1 DD and the late phase leakage 
is less compared with the pre-treatment angiogram of the same eye (left). 
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Figure 2. Patient 4 with a CNV of the right eye and a VA of 0.25 at presentation 
before radiation treatment (left). The VA was 0.1, 30 months after radiation 
treatment (right). Top left, red free picture at presentation. Bottom left, early 
phase at presentation, with well-demarcated hyperfluorescence. Top right, red 
free, 30 months after radiotherapy. Bottom right, early phase post-treatment. 
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Figure 2. Patient 4 with a CNV of the right eye and a VA of 0.25 at presentation 
and a VA of 0.1, 30 months after radiation therapy. Left, late phase at 
presentation. Top right, late phase 30 months after radiation therapy, with a 
central SS of 2 DD. The late phase leakage 30 months after radiation therapy 
(top right) is less compared with the late phase leakage at presentation (left). 
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Figure 3. Bottom right, late phase of the untreated left eye of patient 4 with 
disciform scarring and a stable SS of 6 DD after 30 months of follow-up. There 
is clearly a difference in scar size between the treated right eye 2 DD (top right) 
of patient 4 and the untreated left eye (bottom right). Although the patient had 
slight myopic correction in both eyes (S -2.0), she also had age-related 
peripapillary atrophy. 
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ABSTRACT 
Background: The results of several pilot studies concerning radiation therapy for 
age-related subfoveal choroidal neovasculansation (CNV) have been published 
recently Although positive treatment results have been described, it is not 
known whether this therapy alters the natural course of eyes with neovascular 
age-related macular degeneration (AMD) A randomized controlled clinical trial 
was conducted in which radiation therapy was compared with observation in 
patients with subfoveal neovascular AMD 
Methods: 74 patients with a recent drop in central vision due to subfoveal age-
related CNV were randomized to either radiation treatment or observation 
Patients with either classic, occult or mixed type CNV were included Eyes in 
the treatment group received a radiation dose of 24 Gy in 4 fractions of 6 Gy 
Evaluation of data concerning visual acuity (VA) and fluorescein angiography 
occurred at 3, 6 and 12 months after inclusion 
Results: At 12 months of follow-up 52 2 % of the observation group versus 
32 0 % of the irradiation group had lost 3 or more lines (P=0 03 log rank test) 
More severe visual decline, 6 lines or more, was observed in 40 9 % of the 
observation versus 8 8 % in the irradiation group (P=0 002 using log rank test) 
At 12 months 39 6 % of the observation group and 20 0 % of the treatment 
group had lost their VA to less than 0 1 (P=0 08 log rank test) The size of the 
CNV membrane doubled in 25 2 % of eyes in the observation group versus 20 0 
percent in the treatment group at 12 months (P=0 5 logrank test) Until now no 
side-effects have been observed 
Conclusion: Preservation of visual acuity was significantly better in the 
treatment group compared with the control group at 12 months Nevertheless we 
noted a drop in central vision of 3 or more lines in a substantial part of the 
treatment group Radiation therapy does not prevent visual loss in all patients 
with age-related subfoveal CNV, and whether the treatment benefit at 12 months 
will last after longer follow-up has to be awaited 
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Introduction 
Neovascular age-related macular degeneration (AMD) is responsible for severe 
visual loss in the elderly [14] Treatment of subfoveal choroidal 
neovasculansation (CNV) in AMD is a matter of great concern and debate The 
majority of CNV membranes have some degree of foveal involvement and are 
not eligible for laser photocoagulation therapy [1,6] Despite the Macular 
Photocoagulation Study Group (MPS) recommendations for laser 
photocoagulation in selected cases of age-related subfoveal CNV, most patients 
and ophthalmologists refrain from this treatment because it leads to immediate 
and permanent central visual loss [1,12,13] Alternative treatments are under 
investigation, including radiation treatment Since the first report in 1991 the 
follow-up of our pilot study has been updated [2,3,4] The Belfast study group 
noted that deterioration of visual acuity (VA) and scar size are less in irradiated 
eyes than in untreated eyes at 6 to 24 months of follow-up [10] Other groups 
confirmed these positive results [2,3,4,5,7] The natural course of CNV's 
depends on the type of CNV on angiography, and large variations between 
patients in these subtypes remain [6,9,11] A clinical trial was conducted to 
evaluate the effect of radiation therapy compared with no treatment for eyes with 
subfoveal CNV in AMD The primary objective of this study is to determine 
whether patients with age-related subfoveal CNV benefit from radiation therapy 
to maintain central vision 
Materials and methods 
The study protocol was approved by the institutional ethical committee 
Eligibility criteria are shown in table 1 The criteria include a history of recent 
drop in VA within 2 months caused by age-related subfoveal CNV and proven 
by fluorescein angiography (FA) The best-corrected VA should at least be more 
than 0 1 Snellen equivalent Patients were referred to the outpatient clinic of the 
University of Nijmegen by ophthalmologists throughout the Netherlands Patients 
who met the inclusion criteria were asked to participate in the trial and, after 
obtaining informed consent, patients were assigned randomly to either radiation 
treatment or observation 
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Table 1 Eligibility entena 
1 recent drop in central vision (within 2 months) 
2 best-corrected Snellen visual acuity > 0 1 
3 angiographically proven classic, occult or mixed type subfoveal CNV 
4 clinical signs of ARM like drusen or pigment epithelial changes 
5 age > 55 years 
6 informed consent 
7 no previous laser photocoagulation in the macular area 
8 no radiation treatment for ear, nose, throat or brain disease 
9 no diabetes mellitus 
Patients had a complete ophthalmic examination including best-corrected distance 
Snellen VA, Amsler grid testing, biomicroscopic shtlamp examination of the 
lens, 35°color fundus photographs and stereoscopic fluorescein angiography of 
the macular area and optic disc of both eyes VA was measured using a Snellen 
chart in a fixed examination unit under standard conditions A visual loss of 3 
lines represents doubling of the minimum angle of resolution, eg, a change from 
20/100 to 20/200, Snellen equivalent A history and a complete ophthalmic 
examination similar to the baseline examination, including angiography, was 
performed at 3, 6, and 12 months, after randomization Fluorescein angiography 
was performed using a standard protocol including early, mid-venous and late 
frames 
Patients who were randomized to the radiation treatment group received a 
total dose of 24 Gy in 4 fractions of 6 Gy, given in an overall time of 3 weeks, 
in the macular area of the affected eye The dose was delivered by two 1 cm2 16 
MV photon beams using a lens-sparing technique [3] To reduce the lens dose 
the beams were directed 30° from the optical axis in the cranial/caudal direction 
and cross the eye axis in the macular area Only the macular area received the 
total dose, outside this area the dose decreased to less than 50 % of the total 
dose The lens received less than 30 % of the total dose The patients in the 
control group did not receive a sham radiation treatment 
Patients with proven CNV on the FA were classified in three subgroups 
according to the MPS criteria patients with classic CNV, occult CNV, and 
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mixed CNV, respectively [12,13] Classic CNV has an area of bright, well-
demarcated hyperfluoresence in the early phase of the angiogram, with 
progressive dye leakage into the overlying subsensory retinal space in the late 
phase Occult CNV can be recognized by two angiographic patterns Type I is a 
fibrovascular pigment epithelial detachment with areas of irregular elevation of 
the retinal pigment epithelium (speckled hyperfluorescence) within one minute 
after dye injection, with persistent staining or leakage in the late phase after ten 
minutes Type II is late leakage of an undetermined source with areas of late 
phase leakage without early hyperfluorescence responsible for this leakage 
Mixed CNV is a CNV with classic and occult components The angiograms 
were independently graded by different investigators (JRV, CBH) 12 months 
after inclusion Discrepancies were openly adjudicated by the same two readers 
Discrepancies that could not be resolved were reviewed for final classification by 
a third ophthalmologist (GJB) The readers were blinded for the treatment status 
The features graded included 1 the type of CNV (classic, occult or mixed), 2 
the size of the CNV lesion, determined by superimposing a transparent sheet 
with printed standard MPS disc area circles (1, 2, 3 5, 4, 6, 9 and 12) over the 
macular lesion [12,13] 
The proportions of patients in the control and irradiation group losing 1 
or more Snellen lines of vision and ending up with a VA < 0 1 were expected 
to be 70 % and 30 % respectively [3,4] A two-sided significance level of 0 05 
and a power of 0 90 required 32 patients in both the treatment group and control 
group To anticipate a disability of follow-up and/or non-evaluable patients of 
10 % in each group, 36 patients in both groups were necessary and 72 patients 
would be randomized into the trial 
Differences in baseline characteristics were analyzed using t-test for 
comparing independent samples means Visual acuity scores and CNV lesion size 
were subgrouped in ordered variables Comparison of ordered variables was 
performed using Chi-square test for trend on one degree of freedom End points 
for VA decline was defined as 3 or more lines drop and 6 or more lines decline 
Other end points that were compared between treatment and observation group 
were VA less than 0 1 and doubling of CNV size Comparison of occurrence of 
end points in the treatment groups during follow-up was done with Kaplan-Meier 
curves and logrank tests 
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Results 
Initially, 74 patients were included in the study Of these, one died and two 
stopped before the first control, one because of fear of malignancies due to the 
treatment In addition, one was excluded because of previously unnoted diabetes 
mellitus and two patients showed insufficient evidence for CNV on the 
angiogram later on As a result 68 patients, 36 treatment group and 32 
observation group, completed at least three months follow-up Twelve months 
follow-up was obtained in 63 patients (Table 2) The baseline characteristics of 
both groups are shown m Table 3 Patients in the treatment group were slightly 
younger than controls Composition and area of lesion in the study eye, baseline 
visual acuity, presence and size of a neovascular lesion in the fellow eye and 
smoking behavior were similar 
Visual decline of 3 or more lines was observed more frequently in the 
observation group than in the irradiation group (Figure 1) At 12 months, 52 2 
percent of the observation group versus 32 0 percent of the irradiation group had 
lost 3 or more lines (P=0 03 log rank test) More severe visual decline, 6 or 
more lines, was observed in 40 9 percent of the observation versus 8 8 percent 
in the irradiation group (Figure 2, Ρ = 0 002 using the log rank test) After 12 
months, 39 6 percent of the observation group and 20 0 percent of the treatment 
group had lost visual acuity to levels less than 0 1 (P=0 08 log rank test) 
Additional analysis of subgroups of classic and occult or mixed type CNV 
suggests that there is a small effect in the classic CNV subgroup but a more 
pronounced beneficial effect in the occult and mixed type subgroup Differences, 
however, were not statistically significant The size of the CNV doubled during 
the 12 months in 25 2 percent of the observation group versus 20 0 percent in 
the treatment group This difference was not significant (P=0 5 logrank test) 
Table 2 Number (percentage) of cases in the study 
Study Group 
Follow-up 
Treatment Observation 
3 months 36 (100) 32 (100) 
6 months 36 (100) 31 (96 9) 
12 months 34 (94 4) 29 (90 6) 
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Table 3 Baseline characteristics of the study population by treatment group 
Characteristic 
Mean age (SD) 
Gender (% women) 
Composition of lesion 
Classic 
Occult 
Mixed 
Visual acuity 
a 0 1 - < 0 3 
S: 0 3 
Size of lesion, MPS grid 
<, 1 
> 1 - < 2 
> 2 £ 4 
> 4 
Size AMD lesion fellow eye. 
no lesion 
< 4 
> 4 
Smoking 
Never 
Former 
Current 
Study 
Treatment 
(N = 
73 1 
20 
19 
8 
9 
13 
23 
13 
8 
10 
1 
MPS grid 
19 
6 
11 
16 
11 
9 
 36) 
(5 8) 
(55 6) 
(52 8) 
(22 2) 
(25 0) 
(36 1) 
(63 9) 
(40 6) 
(25 0) 
(25 0) 
(9 4) 
(46 9) 
(25 0) 
(28 1) 
(44 4) 
(30 6) 
(25 0) 
group 
Observation 
(N = 
76 1 
18 
16 
8 
8 
15 
17 
15 
11 
8 
2 
15 
10 
7 
16 
6 
10 
32) 
(5 8) 
(56 3) 
(50 0) 
(25 0) 
(25 0) 
(46 9) 
(53 1) 
(417) 
(30 6) 
(19 4) 
(8 3) 
(52 8) 
(Π 1) 
(36 1) 
(50 0) 
(18 8) 
(312) 
P' 
0 07 
0 96 
0 96 
0 51 
0 82 
0 89 
0 97 
' Values are numbers with percentages in parentheses unless stated else ' 
Ρ values from Chi-square statistics for unordered and ordered variables when applicable 
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Discussion 
A visual decline of > 3 lines was found more frequently in the observation 
group than in the treatment group at 12 months of follow-up This result became 
more pronounced concerning severe visual decline of > 6 lines at 12 months 
Although these results are in favor of the treatment group, unfortunately still 
32 0 % of treated eyes showed a visual decline of 3 or more lines at 12 months 
follow up vs 52 2 % in the observation group At 12 months follow-up 39 6 % 
of the observation group and 20 0 % of the treatment group had lost VA to 
levels less than 0 1 The results show an overall benefit of irradiation to prevent 
visual loss at 12 months follow up The differences appear to be mainly caused 
by the beneficial effect of irradiation of eyes with occult or mixed CNV's A 
small beneficial effect was seen in classic CNV only Irradiation had no 
significant effect on CNV size doubling but irradiated lesions tended to show less 
increase in size at 12 months follow-up 
Concerning these findings we have to discuss some methodological 
points Differences in the course of the disease in the treatment groups could 
have occurred due to differences in baseline characteristics As can be seen from 
table 3, however, the baseline measurements were very similar and it is therefore 
unlikely that they are the cause of the differences in outcome The results are 
conform the expectations of the pilot study with respect to a beneficial effect of 
irradiation [4] Both treatment and observation group show a better course than 
expected however This is likely to be caused by the use of more strict inclusion 
criteria in this randomized trial Furthermore it suggests that the natural course 
of subfoveal CNV, with respect to the inclusion criteria, is less worse than 
anticipated Although the observers were blinded for treatment status, the 
patients were not This may have influenced the measurements of central vision 
But it is unlikely that this single blind situation may have caused the differences 
between treatment and observation group Differences in lesion size were less 
pronounced than could be expected from the differences in visual decline Partly 
this may have been due to the measurement of the lesions, e g growth of a 
lesion can occur within the limits of the baseline disc area On the other hand 
these results are based on objective criteria 
Many uncontrolled pilot studies concerning radiation therapy for 
subfoveal neovascular AMD have been published with promising results but 
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without definite proof of the efficacy of radiation treatment [2,3,4,5,7,10] After 
at least 30 months post-treatment with 24 Gy (6 Gy fractions) 5 out of 10 eyes 
with subfoveal exudative disease remained stable concerning VA and lesion size 
in our pilot study [3,4] The Belfast study group found a treatment benefit on 
central vision at 12, 18 and 24 months after irradiation and also a reduction of 
disciform scarring [10] In their study VA in treated eyes and VA in untreated 
eyes had worsened on average by 12 7 % and 52 7 % respectively at 12 months 
follow-up [10] 
The main objective of irradiation is to induce inactivation of the CNV 
membrane with reducing the risk of subretinal fluid leakage or bleeding and 
subsequently leading to either stabilization of central vision and/or to a reduced 
scar size [3,5,7,10] There is no acute visual loss as does occur with laser 
treatment and until now no severe side-effects were encountered, although two 
patients experienced temporal conjunctival injection after treatment Maintenance 
of VA above a level of 0 1 Snellen acuity offers the patient the possibility to 
keep some visual function and to benefit from low-vision aids, most important in 
patients with exudative disease in both eyes Excluding eyes with a VA less than 
0 125 offered the opportunity to determine a substantial drop m VA, important in 
the prevention of legal blindness Many patients presenting with subfoveal CNV, 
however, have Snellen VA of < 0 1 and will not benefit from treatment and 
subsequently, were not included in this trial 
Recently data concerning 112 eyes in the natural history group during a 
trial with interferon became available [9] Loss of > 3 lines at 1 year occurred 
in 58 % in the classic CNV group, and 35 % and 37 % in the occult and mixed 
CNV group respectively The difference in visual prognosis in case of classic 
CNV compared with occult and mixed CNV is important Plaque growth, 
reflecting the scar size in disc areas, doubled in 6 months in classic CNV and 
doubled m 12 months in occult and mixed CNV [9] We found that the size of 
the CNV membrane in all subgroups doubled in 27 6 % of the observation group 
versus 20 6 % in the treatment group, which was not significantly different 
We used a total dose of 24 Gy with a fraction size of 6 Gy in 3 weeks only in 
the macular area (1 cm2) This dose is biologically equivalent to 50 Gy in 25 
daily fractions of 2 Gy [4] This radiation scheme gave the best results in our 
pilot study and offers the possibility to give a relatively high dose in the macular 
area without exceeding the tolerance levels of surrounding ocular tissues 
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Although this dose exceeds the total dose of 15 Gy (3 Gy fractions) used by the 
Belfast study group, our treatment volume is small compared with their 
technique of lateral irradiation [10] Radiation retinopathy and cataractogenesis 
was not observed as expected with a total dose m the macular area of 24 Gy and 
a 12 months period of follow-up 
In conclusion our results show that there is a beneficial effect of radiation 
therapy for age-related subfoveal CNV at 12 months follow-up Preservation of 
central vision was significantly better in the treatment group vs the observation 
group Unfortunately, we noted a drop in central vision of 3 or more lines in a 
substantial part of treatment group Furthermore, we angiographically noted 
growth of neovascular membranes with progressive leakage in irradiated eyes, 
which at least indicate that not all treated neovascular membranes respond with 
growth arrest and reduced leakage Although the difference in favour of the 
radiation group concerning a drop in central vision of 3 or more lines at 12 
months was significant, this result has to be taken with caution Irradiation does 
not prevent visual loss in all patients Whether the treatment effect will last for a 
longer period can not be answered yet Until longer follow-up is available we 
will be cautious propagating radiation therapy as a new treatment modality in 
recent age-related subfoveal neovascular membranes 
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12 
Follow-up (months) 
Figure 1. Kaplan-Meier curve for the proportion of eyes with decreases in visual 
acuity of 3 or more lines from baseline to each follow-up examination. Solid line 
indicates irradiated group (n=36), dashed line indicates observation group 
(n=32). P=0 03 using the log rank test. 
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Figure 3. Left eye of patient treated with radiotherapy in the randomized trial. 
An example of a stabilisation of a CNV membrane and visual acuity after 
treatment with radiotherapy. Top left, early phase of mixed type CNV at 
inclusion. Bottom left, late phase at inclusion. Top right, early phase 12 months 
after radiotherapy. Bottom right, late phase post-treatment. There is no increase 
in lesion size nor in late phase leakage at 12 months after radiotherapy. 
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12 
Follow-up (months) 
Figure 2. Kaplan-Meier curve for the proportion of eyes with decreases in visual 
acuity of 6 or more lines from baseline to each follow-up examination. Solid line 
indicates irradiated group (n=36); dashed line indicates observation group 
(n=32). Ρ=0 002 using the log rank test. 
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8.1 DISCUSSION AND CONCLUSIONS 
Discussion 
This thesis provides new and detailed information concerning radiotherapy for 
age-related subfoveal CNV During the last decades the knowledge about the 
detection, the natural course and laser photococoagulation treatment of CNV 
membranes increased substantially Despite new diagnostic procedures like ICG 
angiography, fluorescein angiography (FA) remains the diagnostic standard for 
detecting CNV membranes [3] What has changed is the description of CNV 
patterns on FA The MPS group propagated a classification based on FA changes 
associated with CNV that could lead to a standard definition of the various CNV 
membranes [1,2] This has the advantage that, for example, a classic CNV 
pattern is interpreted consistently Furthermore comparison of research results is 
more accurate when standard angiographic patterns are used The results of our 
pilot study were compared with natural history data as described by various 
research groups [4,5,6] These data were often but not always based on 
consistent descriptions of angiogram patterns 
The various angiographic patterns of CNV membranes not only are of 
diagnostic help but they also have implications concerning the visual prognosis of 
the involved eye [7] We already knew that the majority of patients with 
subfoveal CNV were expected to develop severe visual loss [1,2] In comparison 
with occult and mixed CNV, classic membranes have a poor visual prognosis at 
12 months [7] Beside the differences in natural course between CNV subgroups, 
differences between individuals make it difficult to predict the outcome of the 
VA for an individual eye Whether the two eyes of one person, with neovascular 
AMD in both, will behave in a same manner concerning visual acuity (VA) and 
disciform scar size is not sure 
A pilot study was started partly based on the findings from basic research 
that considerable changes occur in human capillaries after a single radiation dose 
(8 7 Gy), leading to endothelial cell damage and capillary closure The patients 
treated with 24 Gy (6 Gy fractions) showed the best results after at least 12 
months of follow-up However those treated with 12 Gy and 18 Gy also did 
better at 12 months compared with natural course studies The results of our 
pilot study indicated only CNV stabilisation but no CNV regression after 
irradiation, which differed from the findings of the Belfast study group [5] The 
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reasons that can account for the different outcome between the Belfast pilot study 
and ours are: Firstly the inclusion criteria, with a distinction between the 
duration of several CNV membranes at presentation (> 2 months versus < 2 
months), the baseline VA (some < 0.1 versus only > 0.1) and the presence of 
previous laser treatment (sometimes versus never); Secondly the radiation 
technique (lateral, 4 cm2 versus frontal, 1 cm2), the total dose (10-15 Gy versus 
6-24 Gy) and the fraction size (2-3 Gy versus 6 Gy). Although in our pilot study 
we only noted CNV stabilisation without regression at 12 months, the observed 
scar size reduction compared with untreated fellow eyes at 30 months, supports 
the findings of the Belfast group. No side-effects were observed. 
Our randomized study showed that irradiated eyes show significantly less 
visual loss at 12 months compared with no treatment [8]. This effect appears to 
be mainly caused by a beneficial effect on eyes with either occult or mixed types 
CNV's The effect of irradiation was expected to occur over a period of months 
resulting in a noticeable treatment effect between 6 and 12 months. In the 
randomized study, differences between the treatment and control group were 
already noticable at 3 months and persisted during follow-up [8]. Unexpectedly 
the untreated eyes showed less decline in VA at 12 months, when compared with 
natural history data published by various authors. Nevertheless more than 50 % 
of the observation group had lost 3 or more lines at 12 months follow-up. 
Concerning the lesion size we noted a slight difference in favour of irradiated 
eyes at 12 months. The relevance of these findings must be taken with caution 
because the development of the definite scar will take a longer period. We did 
not observe side-effects so far, however follow-up is still short. 
Questions that remain to be answered in the following years are: 1. What 
will be the optimum treatment technique (teletherapy, brachytherapy, proton 
beam, stereotactic radiotherapy), the optimum total dose and dose per fraction ? 
2. If regression or occlusion of CNV membranes occur, will it result in 
permanent stabilisation of VA and reduced scar formation ? 3. Do classic, occult 
and mixed CNV membranes respond in the same manner ? 4. Can we expect 
long term serious side-effects ? 
The advantage of brachy therapy, proton beam and stereotactic therapy, 
compared with teletherapy, is the possibility to reduce the dose delivered to 
normal tissues. This may lead to less side-effects. Although we have been using 
a total dose (24 Gy, 6 Gy fractions) within the limits of serious side-effects, it is 
145 
Chapter 8 
however not enough to induce and maintain CNV stabilisation or regression m 
all eyes Secondly it is known from our pilot study that a decrease in VA and 
increase in lesion size can occur after a period in which the VA and scar 
remained stable for at least 18 months, presuming a relapse or recurrence of 
CNV Thirdly the natural course of occult and mixed CNV is less deleterious 
than that of classic CNV It is speculative whether a difference in growth speed 
of a CNV, partly reflected in the natural history, can account for an increase in 
effect of radiotherapy Cataract, a possible side effect with current dose schemes, 
is a managable complication Hypothetically, the total dose leading to CNV 
regression in all eyes, will go beyond the limits of serious ocular side-effects, 
like radiation retinopathy Than the outcome may be that treatment with a higher 
dose only to the macular area will result in CNV regression in more patients 
However, the incidence of serious side effects can then be expected to increase 
Conclusions 
Considering the clinical significance of the results outlined in the randomized 
trial we conclude that, despite a significant treatment benefit at 12 months, 
radiation therapy with a total dose of 24 Gy (6 Gy fractions) applied with our 
technique will not prevent visual loss in all patients with recent age-related 
subfoveal CNV [8] Whether radiation therapy results in reduced scar size with 
stabilisation of central vision after longer follow-up has to be seen Radiotherapy 
does not cause an immediate visual loss, as seen after laser photocoagulation 
Until we know the results after at least 2 years of follow-up, we have to 
be cautious recommending treatment with radiotherapy of patients with recent 
age-related subfoveal CNV Furthermore, before we draw definite conclusions 
about the efficacy of radiation therapy for this indication, we have to know the 
results of additional randomized trials using different radiation techniques and 
total doses If the treatment benefit lasts for two years or more we must take into 
account the reduced health care budgets and an aging population with growing 
demands and rising medical costs compared with the medical costs generated by 
those who are legally blind, when considering this potential therapy 
It will be difficult to inhibit the effect of aging on the eye, nevertheless 
prevention of the development and growth of choroidal neovasculansation 
remains of great importance and will remain subject of further investigation and 
research 
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8.2 Summary / Samenvatting 
Age-related macular degeneration is the major cause of severe visual impairment 
in people over 55 years of age in Europe and the U S A The disease is located 
in the macular area, that part of the retina were central vision and color vision is 
located The neovascular stage of the disease leads to severe visual loss Many 
potential new therapies have been investigated, because there is no therapy which 
prevents growth of subretinal neovasculansation and at the same time does not 
destroy photoreceptors and subsequently central vision 
The aim of this study is described in the first chapter The main question was 
whether irradiation of the macular area alters de course of eyes with age-related 
subfoveal neovascular disease 
In chapter 2, the disease age related macular degeneration is described 
Most patients have the dry or atrophic type, and 10 20 % have the exudative 
type with the development of subretinal neovasculansation New capillaries, 
from the choroidal circulation broken through Bruch's membrane, proliferate 
subpigment epithelial and subretinal Beside a genetic predisposition, smoking 
and age are risk factors for age-related neovasculansation Concerning the 
pathogenesis of subretinal choroidal neovasculansation it has been proposed that 
drusen, changes in Bruch's membrane and hypoxia of the outer retina are 
interrelated factors leading to release of angiogenic stimuli 
Fluorescein angiography is the most important value for the diagnosis of 
subfoveal neovasculansation According to the Macular Photocoagulation Study 
Group three types of fluorescein patterns can be described in case of subretinal 
choroidal neovasculansation e g classic, occult and mixed type 
The natural course of eyes presenting with subfoveal choroidal 
neovasculanstion has been described extensively and visual loss to levels < 0 1 
occurred in 70 80 % of eyes within 18 months Although there is a small 
treatment benefit of laser photocoagulation for subfoveal neovasculansation, it is 
no standard treatment because only 13 % of eyes appear eligible and immediate 
loss of central vision occurs after laser treatment Many experimental therapies 
are being investigated including indocyanine green guided laser treatment, 
submacular surgery and retinal pigment epithelium transplantation 
Chapter 3 describes the background of radiation therapy An overview of 
radiotherapy is presented including the influence of fraction size and total dose, 
and furthermore the differences between early and late responding tissue are 
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discussed A review of the possible ocular side-effects of irradiation and the 
results of pilot studies concerning radiation therapy for subfoveal 
neovasculansation are given respectively 
The results of our pilot study are given in chapter 4, 5 and 6 After 
treating groups of patients (n=10) with 8, 12, 18 and 24 Gy total dose in the 
macular area, we observed a positive treatment effect in the last 3 groups We 
decided to do longer follow-up in the 24 Gy (6 Gy fractions) group because of 
the best results concerning visual acuity and scar size compared with natural 
history data Severe side-effects, like radiation retinopathy, were not observed 
during the pilot study 
Chapter 7 describes the results of a randomized clinical trial in patients 
with recent subfoveal age-related neovascular disease This trial, with a control 
group of untreated patients, resulted in better preservation of visual acuity in the 
treatment group at 12 months follow-up Although these results were conform 
the expectations after the pilot study, we conclude that radiation therapy does not 
prevent visual loss in all patients with age-related subfoveal neovasculansation, 
and that the natural course in untreated eyes at 12 months was better than 
expected Furthermore it has to be seen whether radiotherapy results in reduced 
scar size Questions that remain to be answered are 1 What will be the 
optimum treatment technique (teletherapy, brachy therapy, proton beam, 
stereotactic radiotherapy), the optimum total dose and dose per fraction 9 2 If 
CNV regression occurs, will it be a permanent effect ' 3 Do the various 
angiographic CNV types respond m a same manner 9 4 Do long term serious 
side-effects occur 9 
Before drawing definite conclusions concerning radiotherapy for subfoveal 
CNV, results of other randomized trials with different techniques and dose 
schemes have to be awaited 
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Samenvatting 
Leeftijdsgebonden (ouderdoms) macula degeneratie is de belangrijkste oorzaak 
van irreversibele daling van de visus (gezichtsscherpte) bij personen ouder dan 
55 jaar in Noord-Amenka en West-Europa De aandoening betreft de macula 
lutea (gele vlek) in het centrum van de retina (het netvlies) Centraal in de 
macula lutea ligt de fovea centralis De fovea bevat fotoreceptoren, kegeltjes, 
verantwoordelijk voor de gezichtsscherpte en het kleurenzien Ouderdoms 
veranderingen worden in eerste instantie gekenmerkt door de aanwezigheid van 
drusen (afvalstoffen) en van hyper- en hypopigmentaties (veranderingen in de 
pigmentlaag) in de macula 
Klinisch zijn er twee typen van leeftijdsgebonden macula degeneratie te 
onderscheiden te weten de atrofische of "droge" vorm, die bij 80-90 % van de 
patiënten voorkomt, en de neovasculaire vorm, ook wel "natte" of exsudatieve 
vorm geheten Deze vorm ontstaat bij 10-20 % van de patiënten en resulteert, in 
verloop van weken tot maanden, in een onherstelbare ernstige daling van de 
visus Als gevolg van een subretinale neovasculansatie (vaatnieuwvorming onder 
het netvlies) ontslaat er lekkage van vocht, bloed en lipoproteinen onder het 
netvlies van de macula Het eindstadium wordt gekenmerkt door een disciform 
(schijfvormig) litteken en een centraal scotoom (blinde vlek) Voor de 
neovasculaire vorm van leeftijdsgebonden macula degeneratie bestaat nog géén 
goede therapie, alhoewel in enkele geselecteerde gevallen de subfoveale 
neovasculansatie met laserstralen kan worden behandeld Deze foveale 
behandeling heeft echter altijd een directe afname van de nog aanwezige visus tot 
gevolg, maar geeft op den duur mogelijk wel een kleiner litteken en een kleiner 
centraal scotoom Experimentele behandelingen, met als doel de groei van de 
subretinale neovasculansatie te remmen zonder destructie van de retinale 
fotoreceptoren, zijn onderwerp van onderzoek in vele centra 
In hoofdstuk 1 worden de doelstellingen van het onderzoek besproken Bij 
aanvang bestond de veronderstelling dat radiotherapie (bestraling) met een 
maximale dosis ter plaatse van de macula, de groei van subfoveale 
leeftijdsgebonden neovasculansaties kan remmen De belangrijkste beoordelings-
criteria hierbij zijn het beloop van de visus en van het disciforme litteken 
De voorstadia, de verschillende vormen en de mogelijke risico factoren 
van leeftijdsgebonden macula degeneratie worden in hoofdstuk 2 besproken De 
aanwezigheid van drusen en breukjes in de membraan van Bruch, de laag tussen 
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de retina en de chonocapillaris (vaatvlies), en hypoxie (zuurstofgebrek) van de 
buitenste retina lagen zijn waarschijnlijk betrokken bij het ontstaan van angiogene 
(vaatgroei bevorderende) factoren verantwoordelijk voor het ontstaan van een 
subretinale neovasculansatie Als risicofactoren spelen naast leefijd en genetische 
(erfelijke) aanleg waarschijnlijk ook omgevingsinvloeden zoals UV-licht, 
voedingsbestanddelen zoals vitamine С en E en carotenoiden en athérosclérose 
een rol Verder is voor de neovasculaire vorm aangetoond dat roken een zekere 
risico factor is 
Bij het onderzoek van patiënten is het klinisch van belang om met behulp 
van fluorescentie angiografie, de subfoveale neovasculansatie af te beelden 
Volgens recente indelingen kunnen zogenaamde "classsic, occult en mixed" typen 
van subretinale neovasculansaties fluografisch worden onderscheiden Het 
natuurlijk beloop van de typen subretinale neovasculansatie is verschillend 
Meestal groeit een subfoveale neovasculansatie zonder behandeling uit tot een 
groot disciform litteken in de maculastreek Over het algemeen is na 18 maanden 
in 70 tot 80 % van de ogen met een leeftijdsgebonden subfoveale 
neovasculansatie de visus gedaald tot minder dan 0 1 en is er een groot litteken 
ontstaan in de maculastreek 
Hoofdstuk 3 begint met een bespreking van de achtergronden van 
radiotherapie Dan volgt een overzicht van het experimentele onderzoek 
betreffende effecten van bestraling van capillairen (haarvaten) Na bestraling 
nemen capillairen in aantal af en tonen minder lekkage Deze effecten van 
bestraling zouden ook bij de vaatnieuwvorming onder het netvlies kunnen 
optreden Verder worden de invloed van de totale bestralmgs-dosis, de fractie-
dosis evenals de mogelijke korte en lange termijn bijwerkingen van bestraling 
besproken Met name de ooglens is zeer gevoelig Na bestraling kan cataract 
(staar) optreden Ook kan er een bestralmgsretinopathie (netvhesschade door 
bestraling) ontstaan Tot slot volgt een overzicht van de resultaten van de 
verschillende internationale pilot onderzoeken In de meeste centra werden 
bemoedigende resultaten gevonden 
De resultaten van het in Nijmegen verrichte pilot onderzoek, weergegeven 
in de hoofdstukken 4, 5 en 6 werden in artikelvorm gepubliceerd Samenvattend 
werden in de pilot studie groepen van patiënten (n=10) bestraald met een totale 
dosis van respectievelijk 8 Gy, 12 Gy, 18 Gy en 24 Gy Na 1 jaar follow-up 
bleken de ogen bestraald met 12 Gy of meer, minder visus daling te tonen dan 
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op grond van de literatuurstudies omtrent het natuurlijk beloop van de 
aandoening kon worden verwacht Omdat 8 van de 10 ogen in 24 Gy groep na 
12 maanden een stabiele visus toonden werd besloten tot een langere follow up in 
deze groep Na 30 maanden hadden 5 ogen een stabiele visus en bestonden er 
aanwijzingen dat er in de andere 5 ogen, waarvan de visus verder gedaald was, 
een kleiner litteken was ontstaan dan in de onbehandelde tweede ogen met een 
disciform litteken van dezelfde patiënten De littekens in deze tweede ogen waren 
ontstaan conform het natuurlijk beloop, zonder lasertherapie 
Om de positieve resultaten van de pilot studie te objectiveren werd een 
protocol opgesteld voor een gerandomiseerde studie Hoofdstuk 7 is aan deze 
studie gewijd Na loting werden twee goed vergelijkbare groepen patiënten met 
dezelfde afwijking en met dezelfde eigenschappen vervolgd Ogen met een 
recente leeftijdsgebonden subfoveale neovasculansatie kregen, na randomisatie, 
of radiotherapie met 24 Gy (6 Gy fracties) of géén behandeling (controle groep) 
Na 12 maanden follow-up waren er in de met radiotherapie behandelde groep 
significant (statistisch bewezen) minder ogen met 3 of meer regels visus verlies 
dan in de controle groep In de met radiotherapie behandelde groep toonden 
echter 32 % van de ogen 3 of meer regels visus verlies na 1 jaar Radiotherapie 
met 24 Gy en fracties van 6 Gy voorkomt dus niet bij alle ogen met een recente 
subfoveale neovasculansatie een verdere visusdaling 
Alvorens tot definitieve conclusies te komen moeten de resultaten van dit 
onderzoek na 2 jaar follow-up bekend zijn Met name de effecten van 
radiotherapie op het behoud van de visus en de mogelijke effecten op de litteken 
stabilisatie, ten opzichte van onbehandelde ogen, zullen dan waarschijnlijk 
duidelijker zijn Nadat ook de resultaten van de buitenlandse gerandomiseerde 
studies met andere bestralingstechnieken en bestralingsdoses bekend zijn, wordt 
het mogelijk om de plaats van radiotherapie m de behandeling van 
leeftijdsgebonden subfoveale neovasculansaties nauwkeuriger te bepalen 
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Meer en meer leiden wij babbelaars op, mensen die anderen aansturen in 
plaats van zelf iets te kunnen. Alsof vakkennis en leiding geven niet samen 
kunnen gaan. 
(P. Borst) 
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STELLINGEN 
behorende bij het proefschrift 
Radiotherapy for subfoveal choroidal neovascularisation 
in age-related macular degeneration 
G.J. Bergink 

1 Het natuurlijk beloop van ogen met een leeftijdsgebonden (ouderdoms) subfoveale 
neovasculansatie gaat in meer dan 50 % van de ogen gepaard met een visusdahng van 
3 of meer regels m het eerste jaar 
2 In de groep met radiotherapie (24 Gy, 6 Gy fracties) behandelde ogen met een 
leeftijdsgebonden (ouderdoms) subfoveale neovasculansatie is, na één jaar, bij minder 
ogen een ernstige visusdahng opgetreden dan in de onbehandelde controle groep 
3 Radiotherapie is niet de oplossing voor het probleem van de neovasculaire vorm van 
leeftijdsgebonden (ouderdoms) macula degeneratie 
4 Naast deelspecialisten, blijven er all-round oogartsen/chirurgen nodig 
5 Patienten die op een wachtlijst staan voor een poliafspraak of oogoperatie kunnen 
gedurende de wachttijd niet genieten van de door hun zorgverzekeraar gesponsorde 
voetbalclub of sportevenement 
7 De vaak gehoorde uitspraak bij een second opinion "twee weten meer dan één", 
suggereert ten onrechte dat de som der kennis van twee artsen (m/v) over een 
probleem altijd groter is dan die van ieder afzonderlijk 
8 De aandacht voor de scherpte van de schaats is vaak onevenredig groot vergeleken 
met die voor de bolling 
9 Het belang van een goed evenwicht tussen in- en ontspanning blijkt uit de opmerking 
dat de Tour de France in bed gewonnen wordt 
10 Als het carrièreperspectief voor artsen alleen gaat bestaan uit de overstap naar het 
management, ziet de toekomst voor de patient er zorgelijk uit 
11 Het poldermodel is géén mooi Hollands (ver)gezicht en de wet BIG géén beperking 
van het aantal varkens, echter beiden zijn een uitmg van voortschrijdende 
bureaucratie 
Nijmegen, 6 maart 1998 



